2025

Corporate Responsibility and Public Benefit Report

United Therapeutics

A PUBLIC BENEFIT CORPORATION

Unitherians Kyle and Roland at CHEST 2024, an annual conference hosted by the American College of Chest Physicians

Learn more about United Therapeutics by watching these award winning videos:

Revivicor | The Future of Xenotransplantation

https://vimeo.com/1025560274

Miromatrix | Advancing the Art and Science of Bioengineering

https://vimeo.com/1043125520

A First-in-Class Clinical Scale Designated Pathogen Free (DPF) Facility

https://vimeo.com/911193933/32e7535418

***Phase Five* | A LEED Gold GMP Sustainable Warehouse**

https://vimeo.com/856506077

The *Unisphere* | A LEED Platinum, Site Net Zero Commercial Office Building

https://vimeo.com/292412250

Table of Contents

Message From Our CEO 2

Our Purpose 3
Our Business and Purpose 4
2024 Year in Review 5
Where We Operate 6
Our Focus 7
Our 2024 PBC Goals, Corporate Responsibility, and Resilience Priorities 9

Our Patients 12
2024 Highlights 13
Product Innovation and Clinical Trials 14
Organ Research and Development Projects 17
Product Quality and Patient Safety 21
Quality Operations 23
Patient Centricity 24
Market Access and Pricing 27

Our People 28
2024 Highlights 29
Inclusion and Belonging Programs 30
Talent Acquisition, Management, and Development 31
Total Rewards 32
Safe and Healthy Workplaces 33

Our Planet 36
2024 Highlights 37
Eco-Resilience 38

Our Practices 45
Governance 46
Ethics and Compliance 49
Grants and Giving 51
Data Privacy and Security 53
Enterprise Risk Management and Organizational Resilience 54

Reporting Indexes 56
About This Report and Stakeholder Engagement 57
Our 2024 PBC Key Metric Summary 60
GRI Standards 64
SASB Topics 83



This Corporate Responsibility and Public Benefit Report primarily highlights some of our sustainability efforts during 2024. Throughout this Report, we also call out 2025 highlights. This Report is not a comprehensive description of all of our efforts during the reporting period.

Forward-Looking Statements

This Corporate Responsibility and Public Benefit Report (this Report) contains forward-looking statements made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995 (**PSLRA**). These statements, which are based on our beliefs and expectations as to future outcomes, include, among others, statements and opinions about our future operating results, business plans, objectives, pipeline advancements, benefits of our products, and corporate responsibility or public benefit matters, including information or aspirations regarding sustainability and the environment, employees, philanthropy, supply chain, ethics and governance, cybersecurity and data privacy, and any others that contain the words believe, seek, aim, strive, endeavor, expect, anticipate, intend, estimate, should, could, may, will, plan, or similar expressions, and any other statements contained or incorporated by reference into this Report that are not historical facts. These forward-looking statements are subject to certain risks and uncertainties, such as technological advancements, energy prices, government incentives, stakeholder engagement, and those described in our periodic reports filed with the Securities and Exchange Commission (**SEC**) that could cause actual results to differ materially from anticipated results. These statements may also be based on historical or current goals, targets, aspirations, commitments, or estimates; standards for measuring progress that are still developing; diligence, processes, and internal controls that continue to evolve; certifications, representations, or data provided or reviewed by third parties, including information from acquired entities that may be incomplete, subject to ongoing review, pending integration into our reporting processes, or unable to be integrated into our processes; and on assumptions that are subject to change in the future. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the SEC, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the PSLRA for forward-looking statements. We are providing this information as of the date of publication of this Report and assume no obligation to update or revise the information contained in this Report whether as a result of new information, future events, or any other reason. Inclusion of information in this Report is not an indication that the subject or information is material to United Therapeutics' business or operating results, our stakeholders, or our impacts on other parties or corporate responsibility matters, in each case under U.S. securities or any other law or requirement that may be applicable to us. Website references and hyperlinks provided throughout this Report are provided for convenience only, and the content on the referenced websites is not incorporated by reference into this Report, nor does it constitute a part of this Report.

Message From Our CEO

Reflecting on 2024 at United Therapeutics (**UT**) fills me with pride, humility, and determination.

I am **proud of our progress**.

In 2024, we achieved several significant milestones. To name just a few: we served more patients, generated more revenue, developed and retained our amazing employees (we call ourselves "*Unitherians*"), celebrated our 500th successful transplantation of human donor lungs recovered through our full-service *ex vivo* lung perfusion (**EVLP**) service, and opened our first designated pathogen free (**DPF**) facility in Virginia to support our xenotransplantation efforts. Meanwhile, we broke ground on another "first ever" building. This pharmaceutical manufacturing facility in North Carolina will be a mass-timber structure designed for zero embodied energy and low carbon operations and is yet another manifestation of our ambition to operate sustainably while we develop therapies that save people's lives.

I am **humbled by our brave patients**.

On a personal note, my wife **Bina** and I celebrated the 40th birthday of our daughter **Jenesis**, whose diagnosis with pulmonary hypertension led us to start UT in 1996. Recognizing the 15th anniversary in 2024 of the FDA's approval of nebulized Tyvaso® — a therapy that has also helped so many thousands of other people and their families — reminds me of those early, difficult days. We never gave up!

Which brings me to **determination**. We at United Therapeutics are resolved to continue this amazing work.

At UT, we use **science for people, create value based on core values**, and are committed to **eco-resilience**. What this means is that we aim to move quickly from theoretical to practical science, to attract and retain the rare talent who can bring our purpose to life, to do this work with integrity while enhancing the long term wealth for our shareholders, and to operate sustainably to mitigate potential negative impacts and manage future risks.

Pride in who we are and what we have accomplished, **humility** in serving our brave patients, and **determination** to continue this important journey. Outside of our core values, I can't imagine three better words to describe who we are at UT.

I hope you enjoy reading this Report on our work in 2024 and look forward to continuing to share this ongoing journey forward with you.

Onward!

Dr. Martine Rothblatt
Chairperson and CEO

Our Purpose

4 Our Business and Purpose
5 2024 Year in Review
6 Where We Operate
7 Our Focus
9 Our 2024 PBC Goals, Corporate Responsibility, and Resilience Priorities

Our Business and Purpose

UT show booth

UT was founded in 1996 by parents trying to save the life of their child who had been diagnosed with a rare and terminal disease called pulmonary hypertension (**PH**). At the time, there were limited therapies, and the only known cure — then and now — is a lung transplant.

Saving lives is our priority. That is why, following the overwhelming approval by our shareholders in 2021, UT became the first-ever publicly traded biotechnology company organized as a public benefit corporation (**PBC**). Becoming a PBC aligned our legal form with our longstanding commitment to serve our patients. We believe it also enhances our ability to create superior, sustainable value for all our stakeholders, including our shareholders.

We are an innovative, commercially successful, dare-to-be-different biotechnology company. Our mission and vision are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, and we do good.

Our **public benefit purpose** is to provide a brighter future for patients through the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. Our first purpose helps delay or avoid the need for a transplant, while the second purpose seeks to enable a patient to receive a transplant when they need one.

To achieve our purpose, we seek to make positive impacts on patients, on our *Unitherians*, and on the planet. This Report summarizes our ambitions and progress toward achieving these aims.

2024 Year in Review

Data as of December 31, 2024, unless otherwise noted

Served more than
15,500 patients
being treated with our therapies

Reached another **record revenue** year of $2.88 billion representing
24% growth
compared to 2023

Achieved approximately
$2.2 million
in revenue per employee,
which ranks second among our compensation peer group*

Celebrated the
15th anniversary
of U.S. Federal Drug Administration approval of nebulized **Tyvaso**

Employed
1,305 employees
across 14 locations

Maintained a low voluntary turnover rate of
4.6% compared
to an 11% industry average**

Provided organs for
two successful xenotransplants in 2024, both into living humans,
bringing the total xenotransplant procedures using UT manufactured **organs to 12**^

Maintained the operational efficiency of our
LEED-certified properties, representing ~20%
of our total square footage

* See our compensation peer group in our 2025 Notice of Annual Meeting of Shareholders and Proxy Statement, page 50.

** Industry data from Aon/Radford Turnover study; data published December 2024 | U.S. Life Sciences: Biotech/Pharma | Date range for 2024 industry data is June 2023–June 2024.

^ This figure includes four xenotransplants into living human patients, and eight transplants into deceased, brain-dead human organ donors with the consent of the donors' families.

Where We Operate

We have two co-headquarters: one in Silver Spring, Maryland, and one in Research Triangle Park, North Carolina. We operate in five countries, principally in the United States. Selected locations include:

- Bromont/Magog, Quebec
- Manchester, N.H.
- Medford, Mass.
- Eden Prairie, Minn.
- Silver Spring, Md.
- Washington, D.C.
- Blacksburg/ Christiansburg, Va.
- Research Triangle Park, N.C.
- Jacksonville, Fla.
- Melbourne, Fla.

Recent Awards and Recognition Highlights

Fortune Great Place to Work® 2025
eighth award

Fortune 100 Best Companies to Work For® 2025

Fortune Best Workplaces in BioPharma™ 2024 (Large)
fifth award

Fortune Best Workplaces for Parents™ (Large)
third award

Fortune Best Workplaces for Millennials™ 2024 (Small and Medium)
fifth award

Fortune Best Workplaces for Women™ 2024 (Large)
second award

Forbes America's Best Companies 2025® **inaugural list**

OUR SUBSIDIARIES

LUNG BIOENGINEERING | Revivicor | miromatrix A UNITED THERAPEUTICS COMPANY | IVIVA A UNITED THERAPEUTICS COMPANY | Unither BIOELECTRONICS

Our Focus

We seek to develop life-extending therapies and technologies for patients in two core areas: rare disease and end-stage organ disease.

The defining characteristics of patients being treated with our pharmaceutical therapies are twofold: their conditions are extremely rare and life-threatening. While we continue to develop and commercialize therapies for these conditions, we view organ manufacturing as a complementary solution for a broad array of diseases — many of which, such as PH, have proven incurable to date through more traditional pharmaceutical and biologic therapies.

Rare Disease

U.S. Patient Populations

PAH
45,000

PH-ILD
30,000

Neuroblastoma
800

Commercial Products

TYVASO® (treprostinil) INHALATION SOLUTION
TYVASO DPI® (treprostinil) INHALATION POWDER

Tyvaso and **Tyvaso DPI** are inhaled prostacyclin analogues approved by the FDA to treat pulmonary arterial hypertension (**PAH**) and PH associated with interstitial lung disease (**PH-ILD**) (WHO Group 3) to improve the ability to exercise. They are:

- The first products approved to treat PH-ILD, and
- The most prescribed prostacyclin therapies in the United States

Important Safety Information **(ISI):** https://www.unither.com/research-and-medicine/tyvaso

REMODULIN® (treprostinil) Injection

Remodulin® is approved by the FDA to diminish symptoms associated with exercise in patients with PAH.

- It is the most prescribed parenteral prostacyclin in the United States, and
- It has been recommended in PAH treatment guidelines since 2003

ISI: https://www.unither.com/research-and-medicine/remodulin

orenitram® treprostinil EXTENDED-RELEASE TABLETS

Orenitram® is an orally-administered prostacyclin analogue approved by the FDA for the treatment of patients with PAH to delay disease progression and improve exercise capacity.

ISI: https://www.unither.com/research-and-medicine/orenitram

adcirca® tadalafil tablets 20mg

Adcirca® is a Phosphodiesterase 5 inhibitor **(PDE5i)*** approved by the FDA for treatment of PAH to improve exercise ability.

ISI: https://www.unither.com/research-and-medicine/adcirca

Unituxin® (dinutuximab) Injection

We also manufacture and commercialize a therapy approved by the FDA to treat neuroblastoma, a rare form of pediatric cancer.

Unituxin® is the first and most prescribed antibody therapy for high-risk neuroblastoma in the United States.

ISI: https://www.unither.com/research-and-medicine/unituxin

* PDE5i's are a type of drug that can affect blood flow and how cells communicate in the body.

Organ and Organ Alternative Manufacturing

U.S. Organ Transplant Data*

48,000+
Organ transplants performed in 2024

~17
Number of people that die each day waiting for transplant

~3.3%
Increase in organ transplants performed (2024/2023)

~100,000
Number of people on the U.S. national transplant waiting list

At UT, we strive to help address the gap between the need and the availability of suitable organs for transplant.

We are innovating solutions that we believe will soon help save even more lives through our xenotransplantation efforts and our work in regenerative medicine for allogeneic and autologous** organ alternatives. In addition, through our EVLP service, we are increasing the number of organs available for transplant today. This work is also helping us build our knowledge about lung functionality, which informs our organ and organ alternative research and development efforts.

Unitherians working in a lab

* According to the U.S. Health Resources and Services Administration (**HRSA**), one new person joins the organ transplant list approximately every eight minutes. Source: "Organ Donation Statistics." HRSA organdonor.gov. https://www.organdonor.gov/learn/organ-donation-statistics. Accessed April 2025.

** "Auto" means self and "allo" means other. The stem cells used in our autologous organ alternatives come from the same person who will get the transplant, so the patient is their own donor. The stem cells used in allogeneic organ alternatives are from a person other than the patient.

Our 2024 PBC Goals, Corporate Responsibility, and Resilience Priorities

Images from around UT

As a PBC, we are required to report to our shareholders on how we are advancing our public benefit purpose and the interests of our stakeholders. We align our PBC goals with our three core stakeholder groups — **Our Patients**, **Our People**, and **Our Planet**. Cognizant of the fact that our work affects and is affected by the world, and that there is significant overlap between our PBC goals, objectives, metrics, and our corporate responsibility and resilience topics, we use our PBC framework as the structure for our corporate responsibility and resilience-related priorities and reporting. In the Reporting Indexes to this Report, we provide an update on our PBC metrics. We also disclose our efforts and impacts in alignment with the Global Reporting Initiative (**GRI**), the Sustainability Accounting Standards Board (**SASB**) standard for our industry, and we reference the United Nations Sustainable Development Goals (**UN SDGs**) we see as most relevant to our business. We intend to publish our Task Force on Climate-related Financial Disclosures (**TCFD**) separately from this Report.

This Report summarizes our ambitions and progress toward our PBC purpose, goals, and objectives. We invite readers interested in or needing more details to explore the wealth of information available in the Reports and Other Resources section on our Corporate Responsibility website and by navigating to the links provided throughout this document.

PBC, Corporate Responsibility, and Resilience Topic Prioritization Approach

The Nominating and Governance Committee of our Board annually reviews and approves any adjustments to our PBC objectives and key metrics, based on recommendations from our cross-functional, management-level PBC Cabinet. The PBC Cabinet was renamed from the ESG Cabinet in 2025 to reflect this team's focus on topics and decisions directly linked to our public benefit purpose and our business strategy. We expect to continue to update our objectives and key metrics as we work toward our purpose with the partners in our supply chain, our collaborators in scientific exploration, and the communities where we work and live.

In 2024, we worked with a third party to conduct an assessment of our priority corporate responsibility and resilience topics to refresh our understanding of those topics that could affect our business, our long-term ability to create stakeholder value, and our ability to fulfill our PBC purpose. In peer reports, these topics are often referred to as "material" environmental, social, or governance topics.* We considered input from internal stakeholders — senior leaders and employees — and integrated feedback from a broad range of external stakeholders, including investors and customers. We also considered industry peers and industry-leading practices, leading rating organizations, and third-party reporting frameworks, including the SASB and the TCFD.

Our process is outlined below:

1. **Identifying Topics:** We used our previous priority topics as a starting point and identified additional corporate responsibility and resilience topics across our value chain for consideration through a detailed review of internal and external sources.
2. **Engaging with Stakeholders:** We refined our list of identified topics through direct engagement with senior leaders, which was further informed by feedback and findings from external stakeholders, such as investor engagement and questionnaires from customers.
3. **Scoring and Evaluating:** We scored each data source and stakeholder group to determine the priority topics for us and their importance to our business. Results were validated by our executive leadership team.

We mapped the resulting topic priority list to our PBC goals and metrics, aligned with our core stakeholders. The illustration on the next page depicts how these topics align with, and support, our PBC purpose. Topics are presented in alphabetical order.

The results of our 2024 assessment reaffirm our corporate responsibility and sustainability journey and inform some of the narrative in this Report. We will continue striving to enhance our disclosures in alignment with these priorities in our future disclosures.

⊕ Learn More

For more details, see About This Report and Stakeholder Engagement on page 57 of this Report.

For details about our Board oversight of our PBC, corporate responsibility, and resilience objectives, see PBC Governance on page 47 of this Report.

* Note: The use of terms such as "material" or "materiality" in this Report is not to be deemed to constitute an admission as to the materiality of any information in this report for purposes of applicable securities laws or any other laws of the United States, nor are we using them as they are used in the context of financial statements and financial reporting.

Our PBC, Corporate Responsibility, and Resilience Priorities

The following chart illustrates our alignment of our PBC framework and top corporate responsibility and resilience priorities.

OUR PURPOSE	To provide a brighter future for patients through the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs			
OUR KEY STAKEHOLDERS	**Our Patients**		**Our People**	**Our Planet**
OUR PBC GOALS	**Address Unserved Needs**	**No Patient Left Behind**	**Be a Destination Employer**	**Operate Sustainability**
OUR PBC KEY METRICS	• Number of patients on therapy • R&D milestones, including clinical trial results, regulatory approvals, and progress on R&D projects	• Patient Assistance Programs (**PAP**) • Reliable supply: Inventory and supply chain reliability	• Voluntary turnover • Inclusion and belonging programs • Employee engagement as measured by surveys • Workforce demographics	• New construction site-net-zero energy when feasible • Environmental data trends (e.g., energy, water, and waste) • Progress toward assurable Scope 1 and 2 greenhouse gas (**GHG**) emissions inventories • Develop initial climate risk and opportunity assessment by end of 2025 • Integrate environmental principles to the extent feasible into new product packaging
PRIORITY CORPORATE RESPONSIBILITY AND RESILIENCE TOPICS	• Clinical trial practices • Health Care Provider awareness and education • Pipeline innovation • Product affordability and accessibility • Product quality and patient safety • Responsible marketing and advertising • Supplier product quality and compliance		Talent attraction, engagement, and development	Carbon GHG emissions Resource use management (energy, water, and waste)
OUR PRACTICES	Key Enablers: Governance, Data Privacy and Security, Compliance Culture and Ethics, and Enterprise Risk and Organizational Resilience **PRIORITY TOPICS:** Ethics and Compliance, Risk, and Crisis Management			

Our Patients

13 2024 Highlights
14 Product Innovation and Clinical Trials
17 Organ Research and Development Projects
21 Product Quality and Patient Safety
23 Quality Operations
24 Patient Centricity
27 Market Access and Pricing

2024 Highlights

We are patient-centric. Creating a brighter future for our patients is our top ambition, which is why we align two of our four PBC goals — **Address Unserved Needs** and **No Patient Left Behind** — with our patients. It is also why we align several priority corporate responsibility topics with this important stakeholder group.

Address Unserved Needs

We aim to conduct the most insightful clinical trials with our medicines in areas of high unmet medical need.

No Patient Left Behind

We aim to ensure that all patients who are appropriate for use of our medicines can do so, regardless of their financial situation.



Dorothy Esce, transplant recipient of donor lungs processed through UT's EVLP service, shown here working in her sewing room

More than **15,500 patients** started or continued treatment on our therapies, including 162 patients benefiting from our centralized EVLP service; celebrated the 500th transplant of a lung processed through our EVLP service since its launch

Invested **$481 million** in **R&D** in 2024

Supported **15 ongoing clinical trials** with more than **3,000 volunteer** participants

Full enrollment of *TETON 2* study of inhaled treprostinil for the treatment of idiopathic pulmonary fibrosis (**IPF**), part of a three-study global *TETON* clinical trial program evaluating the use of inhaled treprostinil in IPF and a similar condition, progressive pulmonary fibrosis (**PPF**)

Secured Investigational New Drug (**IND**) clearance for our phase 1 **miroliver*ELAP*®** clinical study in 2024 and submitted IND for the UKidney™ *EXPAND* study (cleared in 2025)

Launched our **first DPF facility** to produce xeno-organs

Provided organs for two successful xenotransplants in 2024, both into living humans*

Provided patient assistance and support programs, delivering education, insurance navigation support, and more to over **34,000 patients** since 2010, including a **$0 co-pay card** for PH products for eligible patients

Launched a **new integrated patient assistance program** for PH products, called **United Therapeutics Cares**

Had zero good manufacturing practices (**GMP**) related issues at UT-owned facilities that would prevent use or approval of our products

Maintained **two-year or more inventory** for most of our therapies

* Our xenotransplant products are investigational-stage products. UT is preparing for clinical trials of our xenokidney, xenothymokidney, and xenoheart products. The two xenotransplants into living humans in 2024 using UT organs were authorized by the U.S. Food and Drug Administration (**FDA**) under the expanded access pathway, sometimes called "compassionate use."

Product Innovation and Clinical Trials

We are patient-centric. We love people. We love science. We love using science to help people.

Our product portfolio helps to address the critical and unmet needs of patients with rare diseases and end-stage organ disease.

PH Therapies

With a focus on rare lung diseases, most of our FDA-approved therapies are concentrated in PAH and PH-ILD. We are actively working to improve our delivery systems to administer these therapies in ways that enhance convenience, safety, and patient outcomes. We are also studying additional indications for our leading product, Tyvaso — notably our *TETON* program consisting of three phase 3 studies of nebulized Tyvaso for the treatment of pulmonary fibrosis (**PF**). Our near-term pipeline also includes a new therapy called ralinepag, for the treatment of PAH.



About Pulmonary Hypertension

PH is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart.

PAH is one form of PH that affects the blood vessels in the lungs and is characterized by increased pressure in the pulmonary arteries, which are the blood vessels leading from the heart to the lungs. The elevated pressure in the pulmonary arteries strains the right side of the heart as it pumps blood to the lungs. This eventually leads to right heart failure and death.

PH-ILD is a rare and serious progressive disease that results from a combination of high blood pressure in the lungs — caused by narrowing of the blood vessels, which forces the heart to work harder — and one or more of a group of progressive lung disorders that cause lung tissue to stiffen, making it harder to breathe.

The only known cure for PAH and PH-ILD is a lung transplant.

Unitherians working in a lab

UT Wall of Inventors

Oncology Therapy

Neuroblastoma is a cancerous tumor that begins in the nerve tissue of infants and very young children. Unituxin was the first antibody therapy approved by the FDA to treat children with high-risk neuroblastoma.

Clinical Trials

Clinical trials assess the safety and efficacy of our medicines, medical devices, and transplantable organ and organ alternatives. Clinical trials in rare diseases face challenges because of small patient populations, among other factors. We are grateful to the patient-volunteers who make our clinical trials possible.

In 2024, we had nearly 3,000 patient-volunteers participating in 15 clinical trials. During the past year, regulatory inspections of our clinical trials resulted in zero required voluntary or official actions or monetary fines.

Most human clinical trials must be registered with www.clinicaltrials.gov. We are committed to conducting our trials in compliance with laws, regulations, and guidelines for the protection of human subjects, including guidelines issued by the International Council for Harmonisation: Good Clinical Practice (**ICH-GCP**). We conduct compliance audits related to our clinical trials and are subject to periodic external audits by health authority inspectors.

Our teams understand that non-medical factors — such as education and awareness — can influence health outcomes, and that the more aware and educated health care professionals (**HCPs**) and patients are about these diseases, the more effectively we can reach underserved populations. That is why we believe our patient education and empowerment efforts, HCP support, and training for nurses and pharmacists in specialty pharmacies (**SPs**) are critical to providing effective management of the diseases we cover. Just as important is HCP knowledge and awareness of clinical trial opportunities for their patients. We continue to work with HCPs to increase awareness of our clinical trials.

Organ and Organ Alternatives

The only known cure for end-stage life-threatening diseases like PAH, PH-ILD, PF, and many others is an organ transplant, but only a small percentage of donated organs are available to address the vast need. For this reason, we are working to create manufactured organs and organ alternatives to address the shortage of kidneys, hearts, lungs, and livers available for transplant. We believe an unlimited supply of tolerable, transplantable organs and organ alternatives will help eliminate the transplant waiting list and cure end-stage organ diseases for which transplant is not currently an option.

In 2024, the FDA cleared the phase 1 study of our product known as miroliver*ELAP*, the first-ever bioengineered alternative organ cleared to enter a human clinical trial. In 2025, we received FDA clearance to initiate a clinical study of our investigational UKidney xeno-organ product, which is derived from a gene-edited source pig.

Milestones such as these are possible because of the efforts of the tenacious *Unitherians*, who are bringing these aspirations to reality. They are also possible because of the brave patients and their families who participate in clinical trials, the thousands of donors and their families who have selflessly donated their organs for transplant, and the handful of patients and families who have agreed to try our investigational-stage organs. We are humbled by their courage and grateful for their trust.

Unitherian in a UT research lab

⊕ Learn More

Corporate website: https://www.unither.com/home
Corporate website > Research and Medicine > Clinical Trials
Corporate website > Research and Medicine > Therapeutic Areas
Corporate website > Research and Medicine > Pipeline

Corporate Responsibility website, Reports and Other Resources:
https://corporateresponsibility.unither.com/reports-and-resources
Corporate Responsibility website > Reports and Other Resources > Patient Safety and Vigilance Overview

This Report: Patient Centricity starting on page 24.

Organ Research and Development Projects

According to the U.S. Health Resources and Services Administration, around 100,000 Americans are currently waiting for an organ transplant, and more than 6,000 patients — almost 17 every day — die each year before receiving one. More than 89,000 patients are waiting for kidneys, close to 10,000 for livers, over 3,400 for hearts, and almost 1,000 for lungs. Many more patients suffering from end-stage organ failure are ineligible for the strict organ transplant waiting list but could benefit from a readily available supply of organs on demand.

Our organ and organ alternative manufacturing efforts consist of three platforms: xenotransplantation, allogeneic regenerative medicine, and autologous regenerative medicine. These platforms encompass four different organs and organ alternatives — kidneys, hearts, livers, and lungs. These groundbreaking programs are intended to address the ongoing shortage of transplantable organs for patients with end-stage organ disease.

In addition, through our EVLP service, we are increasing the number of organs available for transplant today while also building our knowledge about lung functionality, which informs our organ and organ alternative research and development efforts. Meanwhile, we are investing in new services to help ease the administrative burden associated with organ procurement and transportation and engaging with academic centers and researchers at the forefront of transplant science.

Three Platforms with Four Organs and Organ Alternatives

XENOTRANSPLANTATION	 **UKidney™**	 **UThymoKidney™**	 **UHeart™**	
ALLOGENEIC REGENERATIVE MEDICINE	 **miroliver*ELAP*®**	 **mirokidney®**	 **miroliver®**	 **ULobe™**
AUTOLOGOUS REGENERATIVE MEDICINE	 **IVIVA Kidney™**	 **ULung™**		

Xenotransplantation

Xenotransplantation is the use of living cells, tissues, or organs transplanted between different species. UT is using xenotransplantation to address unmet medical needs in humans by using porcine organs. Acquired by UT in 2011, Revivicor was the first organization to clone pigs successfully. We received FDA approval in 2020 for use of our **GalSafe**® pig as a source for food and human therapeutics. GalSafe pigs contain a single gene edit to disrupt the gene responsible for producing the galactose-alpha-1.3-galactose carbohydrate, called "alpha-gal," on the surface of cells. The presence of alpha-gal causes an immune response in humans and is an important cause of rejection.*

Highlights

- Since 2022, we have been involved in 12 groundbreaking transplants of our investigational-stage, gene-edited UKidney, UThymoKidney, and UHeart, including two in 2024. These figures include four xenotransplants into living human patients, and eight transplants into deceased, brain-dead human organ donors with the consent of the donors' families. The data from these procedures have been or are expected to be published in medical journals.
- We opened our first DPF facility in February 2024 and expect the facility to supply xenografts under cGMP** conditions for human clinical trials, with an initial capacity of up to 125 organs per year.

Unitherian in a Revivcor lab

Allogeneic Regenerative Medicine

Through our regenerative medicine and bio-artificial bioengineering programs, we seek to engineer organs using porcine organ scaffolds combined with human donor (allogeneic) cells to produce human-like organs.

Highlights

- In 2024, UT subsidiary Miromatrix received the first-ever FDA clearance of a human clinical trial of a bioengineered organ — miroliver*ELAP*, an investigational-stage external liver assist product (**ELAP**) designed to provide liver support in critical care settings.
- Our Regenerative Medicine Laboratory in Research Triangle Park (**RTP**), N.C. annually produces approximately **2 trillion human lung cells** for use in producing over 200 bioengineered organ alternatives per year for pre-clinical testing and eventual transplantation studies.

Unitherian in a Miromatrix lab

* Boyle, Patrick. "How pig organs made their way into humans: The slow advance to transplant kidneys and hearts." *Association of American Medical Colleges*. 23 Feb 2022. https://www.aamc.org/news/how-pig-organs-made-their-way-humans-slow-advance-transplant-kidneys-and-hearts. Accessed June 2024.

** cGMP = current Good Manufacturing Practices. These are manufacturing practices and controls that are designed to ensure that manufactured products are consistently produced and controlled according to set quality standards.

Autologous Regenerative Medicine

Our bodies' immune systems have evolved to protect us from substances or objects they recognize as "foreign" and reject them. Except for rare transplants between identical twins, organ transplantation — whether allotransplantation or xenotransplantation — has historically required recipients to take immunosuppressive drugs to prevent rejection of the transplanted organ. Through our autologous regenerative medicine program, we seek to engineer organ alternatives using human induced pluripotent stem cells (**iPSCs**), which are cells reprogrammed from mature, differentiated cells to a state that has the capacity to differentiate into almost any cell type in the body. By generating the necessary cell types to build functional organ alternatives from patient-derived cells, we aim to provide truly personalized therapeutics that may not require immunosuppression. The nearly unlimited regenerative potential of patient-derived stem cells may also enable us to provide several grafts over the course of a patient's life.

Highlights

- Our 3D-printed lung scaffold is the most detailed 3D-printed object ever produced, composed of approximately **44 trillion voxels** (voxels are 3D pixels).
- A single 3D-printed lung lobe scaffold includes **200 million alveoli** — about 67% of those in an average human lung — and approximately 4,000 kilometers (close to 2,500 miles) of pulmonary capillaries, roughly the distance between New York City, N.Y., and Las Vegas, Nev.
- Our subsidiary IVIVA is working to develop implantable bioartificial kidneys, research that builds on two decades of peer-reviewed work that has evolved from small animal to human scale — to advanced functions such as gas exchange, blood filtration, and reabsorption.



3D-printed lung scaffold in process

EVLP – Increasing the Number of Lungs Suitable for Transplant Today

Since 2014, we have been developing technologies and services with the aim of increasing the number of human donor lungs for transplant.

In addition to conducting EVLP, our Lung Bioengineering (**LBE**) centralized-service model is designed to provide 24/7, year-round procurement, transport, and logistics support to help practitioners navigate the complicated terrain of transplantation.

Highlights

- In October 2024, we celebrated the 500th successful transplantation of donor lungs treated through our EVLP service, serving more than 162 patients in 2024 alone.
- Our **OrganVue™** software is designed to enable practitioners to remotely engage with LBE Clinical Specialists and make in-depth, real-time clinical evaluations of donor lung viability — at any time, from any location.



EVLP milestone celebration

⊕ Learn More

Corporate website: https://www.unither.com/home
Revivicor: https://www.revivicor.com/
Miromatrix: https://www.miromatrix.com/
IVIVA: https://ivivamedical.com/
Lung Bioengineering: https://www.lungbioengineering.com/
Corporate Responsibility website, Reports and Other Resources: https://corporateresponsibility.unither.com/reports-and-resources
Corporate Responsibility website > Reports and Other Resources > Organ Manufacturing Overview

Innovation Enabling Innovation

Hydrogen-Powered Helicopters for Organ Delivery

The safe and efficient transportation of organs is not easy. Flight or ground transportation delays can close a precious window of viability in which a recipient waits for a life-saving organ to arrive.

Mikaël and images from Unither Bioelectronics

Since its inception in 2017, our wholly-owned subsidiary in Bromont, Quebec, **Unither Bioelectronics**, has reached several groundbreaking milestones. For example, the team completed the world's first successful drone delivery of donor lungs between two hospitals in Toronto in September 2021. In 2022, the team performed the first **all-electric** cross-country helicopter flight. In recognition for these groundbreaking and humanitarian efforts, **Mikaël Cardinal**, VP of Program Management, Organ Delivery Systems, and his team accepted the inaugural Aéro Montréal Enterprise Innovation Award at the 2024 *International Aerospace Innovation Forum*.

Unither BIOELECTRONICS
WE FLY FOR LIFE

Most recently, in April 2025, Unither Bioelectronics completed its proof-of-concept maiden **hydrogen fuel cell-powered** flight — an important step in the journey toward zero-emission rapid organ transportation possibilities.

⊕ Learn More

Unither Bioelectronics: https://www.unither.aero/en/

Learn more from Joe and team members about how they are using "math like a microscope" to try to help advance UT's 3D-printed lung alternative program: https://corporateresponsibility.unither.com/impact-stories/virtual-lungs

Virtual Lungs: Harnessing Math to Advance Science

Employees working at the UT Computational Laboratory for In Silico Molecular Biology (**CLIMB**) are "like meteorologists," explains **Joe Bender**, Senior Director of CLIMB. The key difference is that his team's analysis and predictions are focused not on the skies above, but on the mysteries within. "We are trying to build a digital model of a human lung that is so faithful to the biology of an actual human lung that the FDA approves its use to inform the design of our 3D-printed lungs."



Immunofluorescent image of cultured lung airway cells

Product Quality and Patient Safety

Protecting and improving patient health and quality of life is our core objective and reinforced through our public benefit purpose.

Our first two compliance principles — **WE DO THE RIGHT THING** and **WE ARE PASSIONATE FOR PATIENTS** — link to this core objective, and inspire us to strive toward the following:

- We get the right products, to the right patients, for the right reasons
- We manufacture with the highest quality standards
- We promptly communicate information about adverse events and complaints related to our products
- We proactively observe, assess, and implement required measures to mitigate their effects on patients and improve their overall quality of life

All *Unitherians* are responsible for safeguarding each patient's health, product quality, and helping achieve compliance with UT's policies and standards.

Zero product recalls
in 2024

Global Patient Safety and Vigilance

Global Patient Safety

We monitor the use of our therapies throughout the product lifecycle globally, starting from development programs through post-approval to identify potential side effects, product issues, and institute risk minimization measures to maintain a positive benefit-risk balance. We strive to adhere to best practices in accordance with the latest editions of relevant regulatory and international standards, which include the following:

- Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment, FDA;
- Good Pharmacovigilance Practices, European Medicines Agency;
- Safety Guidelines, International Conference on Harmonisation; and
- Patient Safety, World Health Organization.

We provide mandatory training to our employees and third-party collaborators to help provide for the proper identification, rapid collection, and reporting of adverse events and product complaints related to the use of our therapies.

For details about our clinical trial safety governance and anti-counterfeiting and package serialization approaches, please see the Patient Safety and Vigilance overview in the Reports and Other Resources section of our Corporate Responsibility website.

Unitherian checking inventory

Our Patient Safety, Governance, and Operations

To achieve rapid evaluation of signals* and decision making related to risk-minimization measures, we have established a safety governance structure that operates under a comprehensive and strict set of standards.



Patient safety and safety risk management are at the core of our Patient Safety practice.

Our Patient Safety team regularly monitors reported adverse events and product complaints to identify potential risks that could trigger risk minimization measures. We direct our patients to report suspected adverse impacts by contacting United Therapeutics at 1-866-458-6479, the FDA at 1-800-FDA-1088, or by visiting www.fda.gov/medwatch. Information provided to us is treated in accordance with our Privacy Statement, which is available on our website.

PRODUCT SAFETY REVIEW COMMITTEE (PSRC)

Executive Endorsement

Chaired by our head of Global Patient Safety, and composed of leaders from Patient Safety, Quality, Compliance, R&D, Medical, and Operations, this committee oversees our safety risk management activities. The committee meets at least quarterly to endorse recommended actions proposed by the Product Safety Management Team to protect patient safety based on comprehensive reviews of data across locations, populations, drugs, biologics, devices, and combination products.

PRODUCT SAFETY MANAGEMENT TEAM

Signal Validation and Risk Minimization

Composed of medical, scientific, and quality experts, this team is responsible for evaluating and confirming safety trends or signals and for recommending risk mitigation strategies to the PSRC. The team reports directly to our head of Global Patient Safety.

GLOBAL PATIENT SAFETY AND VIGILANCE

Signal Review and Evaluation

Our head of Global Patient Safety provides strategic and operational oversight of the end-to-end Patient Safety Program and offers vigilance support to Clinical Operations, Quality, Manufacturing, Medical Affairs, and Product Development teams.

⊕ Learn More

Corporate website: https://www.unither.com/home
Corporate website > Patients > Global Product Safety and Pharmacovigilance

Corporate Responsibility website, Reports and Other Resources:
https://corporateresponsibility.unither.com/reports-and-resources
Corporate Responsibility website > Reports and Other Resources > Patient Safety and Vigilance Overview

* A signal is defined as "information that arises from one or multiple sources (including observations and experiments), which suggests a new potentially causal association, or a new aspect of a known association, between an intervention and an event or set of related events, either adverse or beneficial, which would command regulatory, societal, or clinical attention, and is judged to be of sufficient likelihood to justify verificatory and, when necessary, remedial actions." This definition was adopted by the Council for International Organizations of Medical Science in 2010 (https://cioms.ch/publications/product/glossary-of-ich-terms-and-definitions/).

Quality Operations

We are committed to leading industry practice through our **GxP** Quality and Compliance program, supported by a digital Quality Management System. GxP refers to GMP, as well as Good Clinical Practices, Good Distribution Practices, Good Laboratory Practices, Good Tissue Practices, and Good Vigilance Practices. Our Global Quality Policy, along with supporting policies and standard operating procedures, establishes guidelines designed to ensure quality, safety, and efficacy in the marketing and distribution of products.*

⊕ Learn More

Corporate Responsibility website, Reports and Other Resources: https://corporateresponsibility.unither.com/reports-and-resources
Corporate Responsibility website > Reports and Other Resources > Good Manufacturing Practices Overview

Unitherians collaborating on quality assurance

Quality Policy Statement

Unitherians [United Therapeutics' employees] are committed to providing safe and effective therapeutic products to enrich the quality of life for our patients. We will continually achieve our mission through improving scientific innovation, enhancing the quality management system, complying with regulatory requirements, and meeting the expectations of our customers.

GP-001 Revision 02

01/06/2023
Sam Mancuso
Quality Management System Representative
Senior Vice President, Global Quality

1/6/2023
Dr. Martine Rothblatt
Chairperson and
Chief Executive Officer

Our Quality Policy covers all full- and part-time employees and extends to relevant contractors, sub-contractors, and temporary labor. Suppliers that could affect the quality and safety of our products are required to comply with GMP regulations, enforced by the FDA, and have their own Quality Policy, which is expected to be reviewed during qualification and subsequent monitoring.

100% completion
of required GMP training for all new hires and for employees who directly perform GMP activities

Reliable Supply

A cornerstone of our PBC objectives is to have sufficient inventory to maintain an uninterrupted supply to our patients. We aim to have, at a minimum, a two-year inventory of nebulized Tyvaso, Remodulin, and Orenitram, and we work with third-party manufacturers to supplement our supply. We continue to build the operations needed to fulfill our commitment to maintain adequate inventory for our patients, along with the facilities that support this goal. See information about our newest sustainable facility in development on page 42 in this Report — a GMP, mass-timber** pharmaceutical facility we call ***Warp-10*** — which will help us meet our inventory goal for Tyvaso DPI. More details are also available in our Impact Story, "Manufacturing in a Tree House: Integrating Net-Zero with Nature Based Design": https://corporateresponsibility.unither.com/impact-stories/tree-house

* We maintain systems, processes, and training designed to adhere to FDA GMP standards and are committed to improvement, striving to apply cGMP across our manufacturing operations.

** Mass timber are engineered wood products that are created by attaching smaller pieces of wood together to create larger structural elements. A building that uses engineered wood as a primary load-bearing structure is considered to be mass timber.

Patient Centricity

In 2024, we launched multiple initiatives to enhance our patient advocacy and patient support programs — moving toward more proactive integrated strategies that align efforts across our operations. Our advocacy vision is to become a leader in patient-driven health care while fostering access and innovation. This work aligns with three domains, as illustrated below.

Our Patient-Centric Engagement Model



In their own words: We asked PAH patients and family members to share why they chose to become PAH Initiative Ambassadors, a program sponsored by UT. Here is what one PAH Initiative Ambassador said:

Nancy: "When I was first diagnosed, I felt suddenly completely alone. Not only that, but I was lost, terrified, and overwhelmed. When I was still in the hospital, I found the PAH Initiative online and I began to see immediately that I was not only not alone, but that people in this very caring community wanted to reach out to me to and ease my worries by sharing experiences and knowledge. The Initiative allowed me to see a future for myself. Over time, helpful tips from Ambassadors helped me to adapt to living with PAH. Articles, videos, and webinars educated me and made me recognize the importance of my role in my treatment."

Education and Collaboration

Our patient-centric objective is to advance early diagnosis and awareness in partnership with patient organizations and HCPs. In service of this objective, we provide free educational resources to help patients, their caregivers and families, and their HCPs to build knowledge and help them embark on these plans together.

Two of our keynote educational programs are focused on rare diseases that are part of UT's therapeutic focus — PAH and other forms of PH, and neuroblastoma, a rare pediatric cancer.

PAH Initiative

Advancing Patient Care in PAH: We launched the PAH Initiative (**PAHI**) in 2019 to provide education and resources for adults affected by PAH. These materials are unbranded, condition-specific, and very helpful to the more than 13,000 patients and caregivers, as well as the 4,000-5,000 HCPs who visit the PAHI website monthly. The PAH Initiative Ambassadors program is one of PAHI's key initiatives.

While the focus of our PAHI is on people living with PAH, we also provide clinically useful information, disease education, and practical tools and resources to educate HCPs and help them improve the lives of patients with PAH by delivering care consistent with expert guidelines. These include:

- Information on the diagnosis, treatment, and ongoing monitoring of PAH, including the use of frequent echocardiographic monitoring of right heart parameters;
- An in-depth discussion of the pathophysiology of PAH;
- Data showing the importance of risk assessment in determining prognosis;
- Risk calculators to assess risk status;
- Information on treatment approaches; and
- Education to support ongoing monitoring.

Resources include videos and podcasts by experts in PAH, recent academic publications about PAH, training through a comprehensive educational curriculum, and more.

Advancing Patient Care in PH-ILD: Patients with interstitial lung disease (**ILD**) are at elevated risk of developing PH. Beginning in September 2024, our teams launched an educational campaign for HCPs and their patients with ILD about their risks of developing PH to support earlier diagnosis. These materials are branded under our PH-ILD therapies.

NEUROBLASTOMA*info*

Pediatric Cancer Education: While UT is likely best known for our leadership in PH and transplant innovation, our commitment to addressing unserved medical needs extends beyond PH. Through our oncology division, we are working to support children with high-risk neuroblastoma — an aggressive pediatric cancer often diagnosed at an advanced stage. Our dedication to these patients and their families is deeply personal; many *Unitherians*, including our founder, have experienced the devastation of a serious childhood illness in their own families. This drives us to provide resources that are not only medically informative but also emotionally supportive.

Neuroblastoma*info* educational materials

Our **Neuroblastoma*info*** website is a trusted hub for families and HCPs, offering unbranded educational tools, including the *Skivolo Book Series* — a developmentally appropriate storybook collection for children facing neuroblastoma. The website also features our mental health panel and a recorded discussion with patients, parents, and pediatric experts, offering guidance and connection on topics such as grief, guilt, strength, and healing. In 2025, we are bringing these characters to life with the launch of the *Skivolo Animated Series*, a playful and heartfelt show designed to help children with medical complexity explore big feelings, build resilience, and feel seen through stories that reflect their unique experiences.

Support and Access

United Therapeutics Cares

PAH and PH-ILD therapies are specialty medications that bring with them unique complexities requiring in-depth patient education to enable safe and effective administration. For this reason, we launched an ambitious initiative in 2024 to rethink how we support the patient journey from the ground up through the lens of a patient starting and continuing one of our therapies. Bringing together many of the pre-existing United Therapeutics support teams UT is already known for, along with several new teams and capabilities, our new, unified, ***United Therapeutics Cares*** program provides ongoing, one-on-one education and support for adults diagnosed with PAH or PH-ILD who have been prescribed a UT medication.

Upon enrollment into the United Therapeutics Cares program, a *Patient Navigator* is paired with the patient from the time the initial prescription is written all the way through their therapy shipment, initiation, training, and beyond. The navigator builds a relationship with the patient getting to know their specific needs and then to tailor a support plan to best meet their needs. *Patient Navigators* work closely with a team of *United Therapeutics Cares* professionals to help support, clarify, and streamline the patient treatment journey. These include *Access and Affordability Specialists* who review patient insurance plans and assist with coverage options like copay and financial assistance programs; *Therapy Access Managers* work directly with HCPs to educate on access requirements specific to the patient's insurance plan; and *Nursing Teams* help prescribers, their staff, and SPs learn how to use our products to equip them to better serve patients on UT therapies.

Listening and Learning from Patients

Building on the patient-engagement activities described above, UT is strengthening relationships with advocacy groups to co-create educational content and embed patient perspectives throughout the drug and delivery of care development process — from early research to post-launch activities.

Our dedicated teams work hard to provide appropriate patient access to our treatments, supporting more than 34,000 patients on their treatment journeys since 2010.

UT Patient Navigators

This kind of listening-and-learning feedback loop informed recent developments in our Tyvaso Inhalation Solution packaging redesign project, which resulted in packaging that is easier for patients to handle and offers additional efficiency and environmental benefits compared to the previous packaging (see https://corporateresponsibility.unither.com/impact-stories/when-less-is-more).

⊕ Learn More

United Therapeutics Cares: https://unitedtherapeuticscares.com/

PAH Initiative: https://www.pahinitiative.com/

Neuroblastoma*info*: https://www.neuroblastoma-info.com/

Corporate website: https://www.unither.com/home

Corporate website > Patients > Patient Organizations

Corporate website > Medical Professionals > Medical Education Grants and Scientific Sponsorships

Corporate Responsibility website, Reports and Other Resources: https://corporateresponsibility.unither.com/reports-and-resources

Corporate Responsibility website > Reports and Other Resources > Patient Centricity Overview

Market Access and Pricing

We consider the benefits to patients, society, and the health care system in our pricing approach. This includes consideration of our long-term investments into our R&D efforts, which are essential to make progress toward our PBC purpose.

Our work began in and remains focused on the U.S. and Canadian markets, where we have a track record of contributing to increased disease awareness and providing safe, effective, and quality medicines for all, regardless of their socioeconomic status or background. We work with distributors in certain other regions globally where they have the expertise to secure authorization for distribution.

In the U.S., many independent and third-party health plans pay for patient use of our commercial products. In 2025, UT developed the following pricing principles to guide our pricing approach in the U.S.

Our Pricing Principles

United Therapeutics is committed to innovation and to discovering medicines that help address the impact of serious diseases on patients and their families. In support of this mission, our pricing discussions and related decisions are guided by the following principles:

1. Maximizing the impact of our products on improving the lives and well-being of patients with rare diseases and end-stage organ diseases;
2. Taking into consideration the therapeutic benefits to patients and the benefits to the broader health care system in addressing rare diseases and end-stage organ diseases;
3. Providing appropriate patient and provider access to our products, where those products are medically indicated — including access to therapies for eligible patients in the U.S. who lack insurance or cannot otherwise access the therapies;
4. Maintaining our ability to continue to invest in, and drive development of, innovative therapies that will dramatically improve the lives and well-being of patients with rare diseases and end-stage organ diseases, including through ongoing investments in robust research and development; and
5. Meeting patient demand for our current therapies through infrastructure investment aimed at supporting and/or expanding the manufacturing of our products.



Our People

29 2024 Highlights
30 Inclusion and Belonging Programs
31 Talent Acquisition, Management, and Development
32 Total Rewards
33 Safe and Healthy Workplaces

2024 Highlights

As a public benefit corporation, one of our core objectives is to **Be a Destination Employer** — a place where exceptionally smart, mission-driven people are inspired to do their best work and thrive.

Be a Destination Employer

We aim for United Therapeutics to be a destination employer by creating a mission-centric and inclusive environment where *Unitherians* are inspired by the challenging work ahead of us and the opportunity to grow and advance their careers.

Unitherians in a meeting

Voluntary turnover of **4.6%**, compared to an 11% industry average*

Expanded benefits important to our employees, now offering **medical, dental, and vision benefits** to part-time employees; increasing our adoption assistance program for eligible full-and part-time employees, and more

More than 90% of employees who responded to the Great Places to Work® survey from 2018 through 2025 consider UT a Great Place to Work

Overall workforce demographics: **52%** identify as women, **48%** identify as men, **36%** identify as racially/ethnically diverse, and **64%** identify as white

* Industry data from Aon/Radford Turnover study; data published December 2024 | U.S. Life Sciences: Biotech/ Pharma | Date range for 2024 industry data is June 2023–June 2024

A *Unitherian:* "UT's culture emphasizes respect, collaboration, and recognition. I genuinely feel heard and supported by my team and leadership, and there's a shared commitment to our mission that creates a strong sense of purpose. Whether it's through open communication, flexible work-life balance, or the encouragement to grow professionally, I always feel like a valued and trusted part of the team."

Inclusion and Belonging Programs

We firmly believe that being a great place to work means being an inclusive place to work.

We recognize and value the array of differences represented by our current and future *Unitherians*. We believe we are more innovative, more creative, and make better decisions to serve our patients because of our different perspectives.

Inclusion and belonging have been core principles at UT since our founding. In 2022, we formalized this commitment by establishing Inclusion as one of our five Core Values, clearly defining the expectations for all *Unitherians*:

- We treat others with respect;
- We seek varying perspectives and viewpoints and listen with the intent to understand;
- We value and leverage our rich and diverse experience and talents; and
- We share information and expertise to partner and work together to achieve goals.

In 2024, we began to emphasize our focus on Inclusion and Belonging to reflect our ongoing commitment to equal employment opportunity, and to create a workplace where every employee feels valued, respected, and connected. With this, our intention is to continue our commitment to be a workplace that values diverse perspectives and fosters a culture where every *Unitherian* can be their authentic self and thrive.

The model below and sections that follow provide some of the details about these programs. See our Culture and People Topic Overview — available on our Corporate Responsibility site under Reports and Other Resources — as well as our Career and Benefits pages on the Unither.com website for more information.



2025 Great Place to Work survey responses

94% of *Unitherians* say UT is a great place to work

97% are proud to tell others they work at UT

Talent Acquisition, Management, and Development

100% completion
of assigned incident management, GMP, Code of Conduct training, and human resources curricular

Our culture is unique, so we make a point to be transparent about our purpose, approaches to work, and growth objectives when engaging with prospective job candidates. In every candidate interaction, we strive for open and honest communication, and we seek to regularly improve our recruitment efforts to help us find the next generation of *Unitherians* — wherever they may be.

When a new *Unitherian* joins the team, we seek to prepare them for long-term success. We believe learning should be continuous, employee-driven, manager-supported, customized to the individual based on strengths and development needs, and blended using different modalities. We align with a **70/20/10 training model** which holds that individuals gain 70 percent of their knowledge from on-the-job experiences, 20 percent from interactions with others such as through mentoring, and 10 percent from formal educational events.

We shape our training plans, learning journeys, and course offerings with input collected from people leaders, trends, and areas we have identified that require focus. We also customize courses to address specific team needs, covering topics such as team dynamics, communication, influencing without authority, and inclusion. For example, required training in 2024 included the following:

- Leadership training on building trust and accountability and leading powerful conversations required for all our people managers;
- Management essentials course on UT policy and management responsibilities for new managers; and
- Preventing harassment and discrimination, and training on inclusion and belonging for new hires.



United Therapeutics helps contribute to the development of a pipeline of talent for the entire biotech sector through UT Endowed Scholarships at three local community colleges in North Carolina — Central Carolina Community College, Wake Technical Community College, and Durham Technical Community College. These scholarships help fuel the future success of students who engage with the BioWork certificate program in the region.

Read more about these endowed scholarships and the BioWork program here: https://corporateresponsibility.unither.com/impact-stories/fueling-futures

Total Rewards

Our total rewards, benefits, and wellness programs are designed to attract, retain, and develop our workforce, which is why we continue to enhance our financial security, health, and wellness every year. Benefits include a **living wage**, composed of cash compensation targets of at least $75,000 annually (base salary plus bonus target) for full-time *Unitherians*; an employee stock purchase plan; a **401(k)** program with significant company match; state-of-the-art **fitness centers** and **free cafeterias** at certain locations; access to **medical**, **dental, and vision** benefits for eligible full- and part-time *Unitherians*; **adoption and surrogacy** assistance programs; **parental bonding leave; paid time off** for eligible full- and part-time employees; a **career framework**; **training plans** and **learning journeys**; **reimbursement for continuing education;** and much more.

We recently enhanced benefits offerings in several areas, including providing access to medical, dental, and vision benefits to part-time employees; increasing our adoption assistance program for eligible full- and part-time employees; increasing travel benefits under our medical plan to enable access to medically necessary procedures; and adding a pet wellness benefit. In 2024, we embraced a policy introduced to us by the Miromatrix team: employees are now eligible for paid leave to serve as a bone marrow donor or living organ donor.

For detailed information about the benefits and wellness solutions we provide our employees, see https://www.unither.com/careers/benefits-and-amenities

United Therapeutics' benefits that support working families are among those most appreciated by *Unitherians*. Read an Impact Story about why providing childcare services was a longtime promise our founder and CEO, Dr. Martine Rothblatt, made to future employees, and how this and other UT benefits help working parents and their families today: https://corporateresponsibility.unither.com/impact-stories/happy-families.

A *Unitherian:* "Paternity leave is a much appreciated benefit of working at UT. It has given me a lot of peace of mind knowing I will have the time to transition/adapt to a changing life event."

Childcare center on our Silver Spring campus

Safe and Healthy Workplaces

At UT, we are dedicated to the well-being of our employees. We seek to be a global leader in protecting our people, partners, contractors, and communities in a safe and environmentally sustainable manner.

We continue to see strong interaction with our incident reporting and investigation module that was implemented in 2023 through our overall environmental health, safety, and sustainability management system. Through web-based access to this module, employees can report hazards, near misses, and incidents with greater ease. The data trends provide aid in concentrating global initiatives to reduce hazards, and we believe our data illustrates the success of this system in fostering a culture of reporting with open communication and clear reporting procedures.

Overview of Our Safety Program

The heart of our safety program is prevention. We encourage employees at all levels to contribute actively to our positive safety culture by promoting employee participation on our safety-focused committees and other collaborative initiatives.

Our aim is to eliminate hazards and reduce safety risks where we work. We use the hierarchy of controls, developed by the National Institute for Occupational Safety and Health (**NIOSH**), for controlling workplace hazards and protecting employees.

Our integrated environmental and safety management system helps us control risks, manage centralized reporting, and oversee key aspects of safety and health. Focusing on leading safety indicators rather than lagging safety indicators enables employees to take preventative action to address or eliminate a hazard beforehand. Ongoing improvement is key to our safety program.

Our leaders are expected to incorporate health and safety engineering practices into current processes and future projects. We are dedicated to mitigating risks across our global business operations, where we aim to foster a zero-incident culture while consistently meeting EHSS objectives and targets.

NIOSH Hierarchy of Controls



Source: NIOSH, https://www.cdc.gov/niosh/hierarchy-of-controls/about/

UT Occupational Safety and Health Data

METRIC	2024	2023	2022
Number of fatalities at UT	**0**	0	0
Number of recordable injuries and illness at UT	**10**	11	2
UT recordable injury and illness rate per 100 workers	**0.91**	1.2	0.2
Average industry recordable injury and illness rate per 100 workers	**1.7**	1.6	1.6

Industry data based on annual U.S. Bureau of Labor Statistics Injuries, Illnesses, and Fatalities averages for the pharmaceutical preparation manufacturing industry.

Train to Empower

To establish a common baseline across functions, we provide regular safety training to employees, and in-depth, role-based training where applicable.

In line with our 70/20/10 training model at UT, we take an integrated approach to training, using multiple methods including on-the-job training, shorter micro-learnings, and online modules.

An important objective of our safety program is to help people identify risks and empower employees to speak up. We support several voluntary, employee-run safety committees that were established to facilitate safety conversations across departments and locations. These safety committees seek to empower everyone at UT to create and maintain a safe and healthy workplace by reducing risk and preventing injuries.

Identify and Eliminate

Internal and external auditors routinely audit our health and safety programs and performance. We regularly assess health-related risks to employees, contractors, and visitors, and seek to proactively manage those risks across our operations.

For example, we complete periodic industrial hygiene monitoring studies across our business units. Data from these studies are tracked using our industrial hygiene module within our overall environmental, health, safety, and sustainability management system, allowing us to monitor industrial hygiene for our employees and our environment.

98% of employees

responding to the Great Place to Work survey agree that UT is a physically safe place to work

Improve

We prioritize spotlighting and amplifying leading practices that become part of our safety culture. For example, in 2024, we enhanced EHSS communications in safety committees across our enterprise by discussing a focused safety topic at each quarterly meeting. This strengthens the sharing of safety best practices throughout each UT site.

The EHSS team conducts periodic collaborative reviews of EHSS training programs and SOPs with more than 50 people leaders in Operations and R&D to continually enhance our curricula and support documentation. This shared improvement process enhances our audit readiness, our safety culture, and employee accountability.

A *Unitherian:* "Safety, healthcare, and wellness support demonstrates that UT cares about my well-being."

Unitherians engaging in on-the-job training in a UT laboratory

⊕ Learn More

Corporate website: https://www.unither.com/home
Corporate website > Careers > Awards & Recognitions
Corporate website > Careers > Benefits & Amenities
Corporate Responsibility website, Reports and Other Resources: https://corporateresponsibility.unither.com/ reports-and-resources
Corporate Responsibility website > Reports and Other Resources > Culture and People Overview
Investor Relations website: https://ir.unither.com/corporate-governance
Investor Relations website > Corporate Governance > Corporate Governance Documents > Code of Conduct

Our Planet

37 2024 Highlights
38 Eco-Resilience

2024 Highlights

We believe that acting sustainably and being aware of our environmental impacts are crucial to achieving our purpose and goals related to our planet, which is why we are committed to **Operate Sustainably**.

Operate Sustainably

We aim to mitigate our environmental impact and operate in a sustainable fashion.

Maintained the operational efficiency of our four **LEED Certified** properties, representing about **20%** of our total square footage, and broke ground on our newest sustainable building, a cGMP mass timber pharmaceutical manufacturing facility

Maintained almost **7-MW onsite solar capacity** and **84 electric vehicle (EV) charging stations** across our campuses

Preparing to report Scope 1 and 2 greenhouse gas (**GHG**) emissions

Making progress on our **climate risk** and **opportunity assessment**

Fully converted to smaller packaging with **reduced environmental impact** compared to previous packaging for nebulized Tyvaso

Image shows some of UT's buildings on our urban campus in downtown Silver Spring

Eco-Resilience

Environmental Health, Safety, and Sustainability (EHSS) Policy Statement

At UT, we acknowledge the interconnectedness of life, including how human well-being and the environment are linked. We are committed to complying with all applicable local, state, and federal environmental, health, and safety obligations. Our commitment to social and environmental responsibility is embedded in our public benefit purpose and compels us to advance life-saving therapies in a responsible way that protects our employees, patients, customers, suppliers, neighbors, and the environment. This EHSS policy applies to all employees and contractors at United Therapeutics locations.

Health and Safety. We are dedicated to the well-being of our employees. We aim to eliminate hazards and reduce safety risks where we work. Employees are required to complete annual refresher health and safety training, and we provide employees access to our health and safety policies, procedures, and programs through an integrated environmental health, safety, and environmental sustainability management system.

Environmental Responsibility. We prioritize pollution prevention — on land, in water, and in air — and strive to use energy and natural resources efficiently. This involves installing onsite renewable energy wherever feasible, composting, recycling, repurposing, responsibly disposing of hazardous and nonhazardous wastes, minimizing water use, and returning water to the environment in equal or better quality than we received it.

Climate. We monitor and manage our GHG emissions, implement strategies that bolster climate resilience through the innovative design of our facilities, including the expansion of our site net-zero energy and LEED-certified building portfolio.

Continuous Improvement. We strive to improve our EHSS programs and performance by reporting our progress, both internally and externally. We are dedicated to mitigating risks across our global business operations, where we aim to foster a zero-incident culture while consistently meeting EHSS objectives and targets.

We are committed to developing the highest-quality therapies that improve the lives of our patients while valuing the well-being of our people and communities. Through innovative collaboration and shared commitment to our people and environment, we can create a healthier and more sustainable world for future generations.

EHSS 520.01 Revision 1

Stairwell in a building on our Silver Spring campus

Sustainable Facilities

UT Phase Five warehouse on our RTP campus

We recognize the links between environmental impacts and human health — particularly those related to air quality and climate change, exacerbated by increases in GHGs. We also understand that currently, buildings are estimated to be responsible for approximately 39 percent of global energy-related carbon emissions.* That is why we have maintained a long-standing commitment to addressing the environmental footprint of our built environment through the construction of **site net-zero energy facilities where feasible.** Our recent sustainable building initiatives also consider zero embodied carbon**, and we are increasingly intentional about biophilic design.^

These efforts have inspired our corporate real estate team to collaborate on some of the most innovative and groundbreaking facilities yet seen. The experiences generate lessons we can apply to the new construction projects that follow.

Like any building project, the team must consider trade-off decisions. Patient centricity drives us to prioritize schedule and capacity to produce product. However, sometimes material choices to achieve net-zero embodied carbon can conflict with a net zero energy (operational carbon) goal. For example, the pursuit of energy efficiency can lead to the use of additional insulation materials, which themselves may have higher embodied carbon. As the grids decarbonize, operational carbon associated with energy use is expected to go down. Building operators also have more interventions available to drive down energy consumption after a building is in operation, unlike embodied carbon, which is largely fixed based on design decisions up front. That means that embodied carbon becomes a bigger part of a building's overall footprint over time — and an increasingly important piece of a net-zero carbon facility strategy.

* See https://worldgbc.org/climate-action/embodied-carbon/ for more information about the carbon footprint of buildings.

** A net-zero energy site is one that is optimally efficient and, over the course of a year, generates at least as much renewable energy as it consumes on that site. Site net-zero energy and site net-zero operational carbon are equivalent. A site net-zero embodied carbon building is one where total carbon emissions produced in the production and construction process stages of a building lifecycle, including emissions from raw material supply, manufacturing, transportation, and construction or installation of a building, are reduced to zero. https://worldgbc.org/thecommitment/commitment-glossary/

^ Biophilic design incorporates natural elements, shapes, lighting, and other features to connect the building occupants with nature.

A Journey of Innovation

Proactive facilities management is essential to achieving the performance promise of green buildings. Preventive maintenance programs can provide up to 20 percent savings in raw material use and 30 percent lower GHG emissions compared to operations without such programs.* Our Engineering and Maintenance (**EM**) teams understand that robust maintenance programs can reduce energy and water use, even in conventionally designed buildings, and they seek opportunities to improve efficiencies where possible. For example, our EM team completed a multi-phase lighting retrofit in 2019 on our RTP campus and they are actively exploring new technologies to close loops in our hot water heating systems. Meanwhile, the team is steadily replacing our site operation trucks with EV vehicles; four out of the six of our EM trucks in use on our Silver Spring and RTP campuses are EVs.

2024

Completed our first DPF facility to help expand the availability of tolerable, transplantable organs for patients with end-stage organ disease. The DPF also incorporates sustainability elements such as a **900 kW photovoltaic (PV) array**, white roof for heat deflection, and **energy recovery** on systems to precondition the outside air to maintain high air quality requirements.

2020

Completed our **fourth site net-zero energy facility,** an 11,000 square foot childcare facility on our campus in RTP.

2018

Completed the then-largest, certified commercial **site net-zero energy facility** in North America, *the Unisphere,* in Silver Spring. This **LEED Platinum** facility includes almost 3,000 PV panels with more than **1,000 MWh average annual renewable energy production capacity, 52 closed-loop geoexchange wells**, and more.

2003-2015

Installed our first **92 kW photovoltaic (PV) system** on our first manufacturing facility in Silver Spring.

Secured **LEED Gold certification for two** buildings on our Silver Spring campus.

Commissioned the construction of a **4-MW PV system** on our RTP campus.

2023

Completed our **fourth LEED Certified** facility cold storage cGMP compliant warehouse and logistics center in RTP. Designed toward net-zero energy and lower embodied carbon, this facility, also includes a **microgrid** with battery backup using **Tesla Megapacks** that provide **6.2 MWh of battery storage capacity** to support the building potential grid outages.

2019

Completed our **third site net-zero energy facility** on the campus of the Mayo Clinic, Jacksonville, Fla.

2016-2017

Committed to **site net-zero energy** design for new construction where feasible.

Completed **first site net-zero energy facility** in Melbourne, Fla.

* Roeckel, Guillaume. "The Value of Preventative Maintenance for Achieving Sustainability Goals", Automation.com. 7 February 2024. https://www.automation.com/en-us/articles/february-2024/value-preventative-maintenance-sustainability

2024 Recognition for Phase Five – Project Lightyear during design and construction

Project Lightyear - LEED Gold

2024 USGBC Carolinas Local
Leadership Award

2024 Research Triangle Cleantech Cluster (RTCC)
Cleantech Innovation Award for Energy

2024 International Institute for Sustainable Laboratories (I2SL)
Award for Excellence in Resilience and Renewable Energy

Excerpt from Project Lightyear reveal party book

Warp-10 under construction

Our latest sustainable facility project — what we call *Warp-10* — is a mass timber* pharmaceutical manufacturing facility where we intend to manufacture Tyvaso DPI. This facility is pushing the boundaries of what is possible in green construction. From biophilic design elements that connect our people with nature to covering nearly 40 percent of our energy use with onsite renewable energy and striving toward net-zero embodied carbon, *Warp-10* is a testament to our commitment to sustainable innovation to better serve our patients' needs. Read more about this facility in our Impact Story: https://corporateresponsibility.unither.com/impact-stories/tree-house

⊕ Learn More

Corporate Responsibility website, Reports and Other Resources:
https://corporateresponsibility.unither.com/reports-and-resources
Corporate Responsibility website > Reports and Other Resources > Sustainable Facilities Overview

* As noted on page 23, mass timber are engineered wood products that are created by attaching smaller pieces of wood together to create larger structural elements. A building that uses engineered wood as a primary load-bearing structure is considered to be mass timber. According to the Mass Timber Institute at the University of Toronto, estimates indicate that one cubic meter of mass timber sequesters one metric ton of CO_2, while every ton of manufactured cement produces about half a ton of CO_2. See https://academic.daniels.utoronto.ca/masstimberinstitute/ for more information.

Our Approach to Climate

We believe it is important to measure and manage our climate-related impacts. We have integrated our Scope 1 and Scope 2 data into our centralized software system in alignment with the *Greenhouse Gas Protocol Corporate Accounting and Reporting Standard* (**GHG Protocol**).

We are preparing to disclose our Scope 1 and Scope 2 data in accordance with requirements in the State of California and elsewhere, and we are preparing to disclose our TCFD separate from this Report.

We continue our efforts to retain a robust, data-driven, and comprehensive plan and set of policies to help us mitigate our carbon footprint and better understand climate risks to our business. While we are starting with Scope 1 and Scope 2 emissions, we have begun evaluating our total climate impact, including Scope 3 emissions.

Ecosystem Impact Management

We believe the health of the ecosystems we live in are important to achieve our mission. Our environmental policies are designed to align with ISO 14001 and other applicable environmental laws and regulations. We seek to prioritize pollution prevention in our operations. Our aim is to safeguard natural resources, including clean air and water.

Clean Air

At UT, we have a special connection to breathing. We strive to do our part to help keep the air in the communities where we operate as clean and healthy as possible. For our new facilities, we prioritize installing cleaner-burning natural gas engines, instead of diesel where feasible.

Water Stewardship

We partner with our water and wastewater authorities. Our manufacturing facilities are designed to use water responsibly and operate within regulatory requirements.

We have an outstanding track record in meeting wastewater discharge standards, and we continue to improve water management practices. We have consistently earned water stewardship awards at our Silver Spring, Md., co-headquarters over the last several years, receiving again in 2024 the Washington Suburban Sanitary Commission Gold Level award for consistent compliance.

Responsible Waste Management

Waste management is a key aspect of our sustainability efforts. We seek to manage and minimize waste. We collaborate with our waste management providers and our facilities and operations teams to better manage regulated waste through compliant container storage and labeling, careful packaging, maintaining accurate waste profiles, and shipping to audited storage and treatment facilities. We strive to practice waste minimization through container reuse, landfill free disposal where feasible, and waste-to-energy treatment where appropriate for the material.



Example of *Unitherian* artwork that lines a hallway on our RTP campus

Other Sustainability Initiatives

Beyond our decarbonization efforts, internal environmental management, and regulatory alignment, we continue to look for other avenues to adopt sustainable practices, programs, and policies.

For example:

- Our **commitment to applying green chemistry** principles in our pharmaceutical R&D helps reduce environmental impacts across our product processes. For example, our R&D team undertook a major process development initiative recently to improve the synthesis of one of our therapies. Pending FDA approval, this new process will eliminate the use of certain hazardous reagents, reduce solvent use and energy demand through the process, enhance safety and operator handling, and improve process yield and throughput — all while delivering the same high quality product that meets patient safety requirements.
- Our composting programs at our two headquarters locations — where we diverted more than **187,194 pounds of food waste from landfill in 2024** — allow for the generation of a useful byproduct from food waste and compostable foodservice containers.
- We are members of the **Pharmaceutical Product Stewardship Work Group (PPSWG) MyOldMeds** program, which is designed to provide patients with an easy, safe, and sustainable way to dispose of unwanted, unused, or expired medicines. (https://myoldmeds.com/)
- We have **84 EV charging stations** across our sites, free to use for employees, and we are installing additional chargers to help increase the convenience and affordability of driving electric or hybrid electric cars for *Unitherians*.
- We offer **SmartBenefits®** for *Unitherians* in the DC-metro area to help commuters take advantage of lower carbon local public transit.



When Less is More: How Packaging Redesign Serves Our Patients and the Planet

We concluded a packaging redesign project in 2024 for one of our products. We migrated fully into using the new packaging design by the end of 2024, and anticipate the following benefits from this transition.



up to **73%** **less packaging material** compared to the previous formats

up to **65%** **less plastic**

a decrease in the estimated GHG over the previous packaging format by up to almost **80%**

a reduction in material costs by up to **70%**

Driven by insights from patient experiences and feedback from our warehouse team and specialty pharmacy (**SP**) partners, the work inspired a commitment to integrate environmental principles to the extent feasible into new product packaging. Read more about this Impact Story here: https://corporateresponsibility.unither.com/impact-stories/when-less-is-more.

Our Practices

46 Governance
49 Ethics and Compliance
51 Grants and Giving
53 Data Privacy and Security
54 Enterprise Risk Management and Organizational Resilience

Governance

UT Wall of Honor

We believe our strong corporate governance practices have helped us maintain our focus on our public benefit purpose. Our Board operates through a culture of independent thought and intelligent conversation on critical topics. We have taken a year-round view of corporate governance, adopted leading practices in several areas, and have a robust semiannual shareholder outreach practice led by two of our independent directors.

We welcomed **Jan Malcolm** to the Board of Directors upon election by shareholders at our June 2024 annual meeting. Ms. Malcolm was the Minnesota Commissioner of Health under three governors, and during her tenure she earned a national reputation as one of the first health care leaders to highlight health disparities and the impact of social determinants of health.* She has both operational health care and leadership experience, which complements and supplements the skills of other Board members.

* "Social determinants of health." The World Health Organization. https://www.who.int/health-topics/social-determinants-of-health

PBC Governance

We have an active, engaged, and deeply skilled Board of Directors that oversees our key business strategies and objectives, our risk management process, and our compliance program. Our Board's Nominating and Governance Committee has formal oversight of our corporate responsibility and resilience program and PBC goal setting, performance assessment, and reporting.

The following illustrates our PBC, corporate responsibility, and resilience governance model, which we sometimes use interchangeably with the term "sustainability."

Hallway to the Unisphere

NOMINATING AND GOVERNANCE COMMITTEE

Strategic Oversight

- Provides advisory oversight and governance of our public benefit purpose and our corporate responsibility and resilience program
- Receives updates from the Head of PBC Transparency at least semi-annually on our sustainability and public benefit activities; the entire Board is briefed by the Nominating and Governance Committee on these activities at least annually
- Contracts with external consultants to enhance the Committee's knowledge of sustainability topics, including on climate-related issues

EXECUTIVE LEADERSHIP TEAM

Executive Direction and Support

- Led by our CFO, provides executive sponsorship of our corporate responsibility and resilience program and disclosure decisions
- Reviews and advises on the program, strategy, and priorities
- Meets as needed

PBC CABINET

Stewardship and Action

- Chaired by our Head of PBC Transparency, establishes and oversees execution of corporate responsibility and resilience program, strategy, tactics, and disclosure, including climate-related ambitions
- Represents key functions across the organization, including EHSS, Corporate Real Estate, Human Resources, Finance, Investor Relations, Accounting, Manufacturing, Quality, Legal, Innovation, Enterprise Risk Management, Procurement, and others as needed
- Leads and oversees expert action teams charged with implementing corporate responsibility and resilience priorities
- Typically meets every other month

Board Risk Oversight

We take risk oversight seriously. Each of our Board Committees is responsible for specific areas of risk, providing guidance and oversight to our management team and their efforts to identify and mitigate the risks most relevant to our company.

BOARD COMMITTEE	KEY RISK OVERSIGHT AREA
Nominating and Governance Committee	Enterprise risk management system; corporate compliance program; and PBC and environmental and social sustainability activities, including climate-related risks
Audit Committee	Auditing, accounting, and financial matters, as well as cybersecurity
Compensation Committee	Compensation programs, as well as other human capital priorities

Useful Resources

For additional details about our Board and our corporate governance and business practices, please visit these resources:

Proxy Statement
https://ir.unither.com/investor-resources#sec-filings

Annual Report
https://ir.unither.com/investor-resources#sec-filings

Corporate Governance website
https://ir.unither.com/corporate-governance

Biowalk of Fame featuring Maryland scientists, on the Silver Spring campus

Ethics and Compliance

We prioritize acting with integrity and the highest ethical standards in everything we do. The UT Compliance Program provides structure, governance, and resources to help embed our ethical policies and behaviors across our operations and business relationships.

Our Compliance Principles revolve around the overarching tenet that **WE DO THE RIGHT THING**. Other principles include:

- We are **passionate** for patients
- We **respect** privacy
- We **don't pay to play**
- We communicate **ethically** and **honestly**

We are committed to ethical marketing and sharing important medical information to inform patients, HCPs, and stakeholders. Our Sales and Marketing teams provide education about our products and FDA-approved labels. Under our policies, we prohibit off-label promotion and sales staff are expressly prohibited from responding to questions about off-label information.

Speak up!

Unitherians are encouraged to contact their manager or the Compliance Team to address any compliance-related questions or to raise compliance concerns. Employees may also file a report using EthicsPoint, a comprehensive and confidential reporting tool that maintains a 24/7/365 anonymous phone line.

Learn More

Corporate Responsibility website, Reports and Other Resources: https://corporateresponsibility.unither.com/reports-and-resources
Corporate Responsibility website > Reports and Other Resources > Ethics Overview
Corporate Responsibility website > Reports and Other Resources > Animal Welfare Policy

Investor Relations website: https://ir.unither.com/corporate-governance
Investor Relations website > Corporate Governance > Corporate Governance Documents > Code of Conduct

Unitherians at work

Promotional Communications Policy

All promotional materials must be approved by the Promotional Review Board (**PRB**), led by Regulatory Affairs and composed of representatives from Global Medical Affairs and the Legal Department. The PRB may escalate issues to the President, Chief Medical Officer, Chief Compliance Officer, and Deputy General Counsel for final decision.

Promotional information regarding UT products is required to be truthful, balanced, not misleading, and consistent with FDA labeling. It is expected to describe safety information fully and accurately and must be approved by the PRB prior to use.

Sales and Marketing teams, including new hires, receive training on ethical drug commercialization, helping them to understand our policies and relevant laws before promoting products. Our teams receive ongoing training and are monitored to confirm compliance.

Other key policies in addition to our Promotional Communications Policy include:

- Global Anti-Bribery and Anti-Corruption
- Fair Competition, Anti-trust
- Grants and Other Third-Party Support
- Charitable Contributions

Our Compliance Model

Our Compliance Committee oversees our compliance activities, including the administration of our Code of Conduct and compliance program. It is chaired by our Chief Compliance Officer and composed of senior executives. Twice a year, our Chief Compliance Officer reports to our Nominating and Governance Committee on the activities of the Compliance Committee and Compliance Department.



Grants and Giving

As part of our promise to patients, we fund innovative research projects related to our therapeutic areas of focus as well as organ transplantation. We also recognize the importance of funding initiatives offered by medical societies, hospitals, and patient organizations, including those organizations that host conferences, health and wellness fairs, and patient education events.

We remain committed to being a good neighbor and a good corporate citizen; we provide funding, in-kind donations, and direct service opportunities for employees with many organizations, including those that benefit local communities, support youth, and advance science, technology, engineering, and math (**STEM**) education.

In 2024, we provided approximately **$6.1 million** in grants, sponsorships, and financial donations to just under **140** organizations including FIRST Robotics, Story Tapestries, Inc., the Maryland STEM Festival, Bike Durham, the Orange County Rape Crisis Center, Students to Scholars, Nvolve, and more. This includes $100,000 research grants to two of the three winners of our flagship **Jenesis Awards Program™** in 2024 (a third grantee received his award in 2025), and the endowed scholarships UT established at three community colleges in North Carolina to support students enrolled in biotechnology curriculum programs. Read more about this program in the Fueling Futures Impact Story here: https://corporateresponsibility.unither.com/impact-stories/fueling-futures.

Our catering team in RTP continued to prepare and package meals in 2024 for our neighbors in need, providing 250 meals throughout the year, which *Unitherian* volunteers delivered to Urban Ministries of Durham for distribution. We also provide other in-kind donations to several local colleges and universities and other local organizations.



Highlights of *Unitherians* Volunteering in the Community

Over the past several years, we have sponsored more than 40 volunteer days and facilitated thousands of employee volunteer hours with organizations local to our sites of operation. For example, in 2024, *Unitherians* in Silver Spring **donated toys to help support families at Weller Road Elementary School**, a local Title I school in Montgomery County, Md. For the fourth year running, *Unitherians* in Manchester, N.H., supported the **Southern NH Toys For Tots** drive. Miromatrix *Unitherians* and their friends and family in Minnesota participated in the **Twin Cities Kidney Walk** for the third consecutive year, with **64 participants** who collectively raised **over $5,400** to help fund education, advocacy and support for kidney patients and their families. Revivicor *Unitherians* donated needed consumables and helped **load trucks to take supplies to Hurricane Helene victims, and collectively, *Unitherians* donated over $29,000 to United Way of North Carolina, Salvation Army of the Carolinas, and American Red Cross North Carolina** to help support victims of Hurricane Helene, which UT matched dollar-for-dollar. And, finally, our sales teams **assembled Wee Care Kits** with diapers, wipes, bottles and more for women and families in need.

Unitherian volunteers

Learn More

Corporate website: https://www.unither.com/home
Corporate website > About Us > Corporate Giving
Corporate website > Medical Professionals > Medical Education Grants and Scientific Sponsorships
UT Jenesis Awards: https://www.unither.com/medical-professionals/sponsorships-and-grants/jenesis-awards-program
Corporate Responsibility website, Reports and Other Resources:
https://corporateresponsibility.unither.com/reports-and-resources
Corporate Responsibility website > Reports and Other Resources > Grants and Giving Overview

Data Privacy and Security

At UT, **WE RESPECT PRIVACY**. Gathering and using certain personal information from various sources, including patients, clinical trial subjects, customers, HCPs, and our employees, is core to our business. We are committed to protecting the privacy of this information. We do this through robust data privacy and cybersecurity programs and by driving training and awareness for our *Unitherians*.



Dedicated Data Privacy Email

Our employees, patients, and other third parties can reach us for any data privacy requests or questions at privacyoffice@unither.com.

Learn More

Corporate website:
https://www.unither.com/privacy
Corporate Responsibility website, Reports and Other Resources:
https://corporateresponsibility.unither.com/reports-and-resources
Corporate Responsibility website > Reports and Other Resources > Data Security Overview

Cybersecurity Governance and Process

We use a "defense-in-depth" cyber strategy designed to leverage multiple layers to protect our information and build operational resiliency. We also emphasize innovation so that our information systems enable continued patient-focused R&D innovation. We have established a robust cybersecurity governance structure that operates under a comprehensive and strict set of standards.

BOARD AUDIT COMMITTEE	**Oversight** The Senior Director of Information Security, Risk, and Compliance provides written reports to the Chair of the Audit Committee each quarter and leads a discussion with the full Audit Committee and independent auditor annually.
EXECUTIVE LEADERSHIP	**Strategy Development** The Senior Director of Information Security, Risk, and Compliance reports directly to the Chief Information Officer, who in turn reports to our Chief Operating Officer. We have a highly-engaged executive leadership team that understands and is aligned on our cybersecurity approach.
CYBERSECURITY MANAGEMENT	**Strategy Execution and Operational Management** The Information Security Team leverages the National Institutes of Standards and Technology Cybersecurity Framework. The Data Privacy Office and Information Technology operations teams, led by the Senior Director of Information Security, Risk, and Compliance, collaborate on implementing proper controls for data protection and data use. Information Technology security team members have industry-leading security certifications such as Certified Information Systems Security Professional, Certified in Risk and Information Systems Control, and Certified Information Privacy Manager.

Enterprise Risk Management and Organizational Resilience

The ERM Program is an important aspect of our corporate strategy, and we use a variety of methods to help us appropriately manage our enterprise risks. The Organizational Resilience Program is a central component of our risk management strategy designed to assess, mitigate, and respond to key operational risks across the enterprise.

Learn More

Corporate Responsibility website, Reports and Other Resources: https://corporateresponsibility.unither.com/reports-and-resources
Corporate Responsibility website > Reports and Other Resources > Enterprise Risk Management Overview

Our ERM Governance and Operations

Effective ERM starts with clarity around risk strategy and governance, with the following roles and responsibilities of key stakeholders.

BOARD NOMINATING AND GOVERNANCE COMMITTEE	**Oversight** The VP of Risk Management provides periodic and annual reports to the Nominating and Governance Committee and to the full Board of Directors. In its oversight role, the Committee:	• Maintains awareness of the enterprise risks facing UT and provides guidance • Oversees enterprise risk management activities
EXECUTIVE SPONSORS	**Strategy Alignment** The VP of Risk Management consults with executive sponsors to confirm strategic alignment on corporate objectives and business needs. Executive sponsors:	• Include our CEO, President and COO, CFO, General Counsel, Deputy General Counsel, and EVP, Technical Operations • Maintain alignment between the ERM assessment and corporate objectives • Review ERM outputs and oversees ERM Program Management team • Co-develop any additional risk mitigation strategies, with oversight of the Nominating and Governance Committee, with risk owners
ENTERPRISE RISK PROGRAM MANAGEMENT	**Strategy Execution and Operational Management** The ERM Program Management Team: • Oversees execution of our ERM Program	• Reviews and assesses corporate risks with appropriate stakeholders including risk owners* and interviewees** • Promotes transparency across the enterprise and facilitates risk-informed decision-making through various reporting mechanisms • Regularly reviews and seeks opportunities for improvement of the ERM Program and function

* **Risk owners:** Co-develop risk mitigation strategy with executive sponsors and drive the execution of risk mitigation tactics and escalates challenges or concerns, as needed

** **Interviewees**: Include functional leaders as well as key employees in critical areas to identify and review risks impacting their business area for consideration as potential enterprise risks

Climate-Related Risks

For many, climate risk is business continuity risk. In 2023 and 2024, we analyzed potential physical risks from climate change across our owned and leased operations.

Our latest assessment did not place physical climate risk in the top tier list today; however, we expect to monitor the data annually and will disclose scenarios in our forthcoming TCFD report.

UT apiary installed by Bee Downtown in the pollinator field surrounding our 4-MW solar array in RTP

Reporting Indexes

57 About This Report and Stakeholder Engagement
60 Our 2024 PBC Key Metric Summary
64 GRI Standards
83 SASB Topics

About This Report and Stakeholder Engagement

As part of our commitment to disclosing our corporate responsibility and environmental and social sustainability efforts and ambitions, we published our first Corporate Responsibility (**CR**) Report in 2020. This is our sixth annual CR report and fourth annual PBC Report. This Report references Global Reporting Initiative (**GRI**) Standards, and selected indicators from the Sustainability Accounting Standards Board (**SASB**), now managed by the International Sustainability Standards Board (**ISSB**). We intend to publish separately our Task Force on Climate-related Disclosures (**TCFD**) report alongside our calculated Scope 1 and Scope 2 greenhouse gas emission data in alignment with The GHG Protocol Corporate Accounting and Reporting Standard (**GHG Protocol**).

Please note that information contained in this Report does not constitute a guarantee, commitment, or promise with regard to business activities, performance, or future results and is not intended to create legal rights or obligations. This Report may contain, or incorporate by reference, public information not separately reviewed, approved, or endorsed by UT and no representation, warranty, or undertaking is made by United Therapeutics (**UT**) as to the accuracy, reasonableness, or completeness of such information. For more information, please see the Forward Looking Statements on page 1 of this Report.

The United Nations Sustainable Development Goals (**UN SDGs**) continue to inform our corporate responsibility and resilience priorities. We have identified these UN SDGs as most aligned with our priorities and public benefit purpose.

In addition to the 2025 Report, we include cross-references to the following core UT websites and our other public filings, available on our investor relations website and at sec.gov:

Corporate website:
https://www.unither.com/home

Corporate responsibility website:
https://corporateresponsibility.unither.com/

Investor relations website:
https://ir.unither.com/

Unless otherwise noted, the reporting period for this Report is January 1, 2024 to December 31, 2024, and data covers all employees and operations. Certain metrics and figures throughout the report are approximations and may vary from actual metrics due to rounding.

Below are some of the ways that we actively engage with our broad range of stakeholders — patients, patient organizations, employees, health care professionals (**HCPs**), investors, governmental entities, community groups, and to the planet and its denizens.

STAKEHOLDER GROUP	HOW WE ENGAGE
Patients and their Families	We have several programs through which we deliver support to patients and families, and collect information that helps inform our priorities, including: • *PAH Initiative*, an ever-expanding resource designed to educate and support those diagnosed with PAH as well as their caregivers (https://www.pahinitiative.com/) • Neuroblastoma*info*, a growing resource to educate and support the children diagnosed with neuroblastoma and their families (https://www.neuroblastoma-info.com/) • *United Therapeutics Cares*, our dedicated support team for insurance coverage, financial assistance, and other questions (https://unitedtherapeuticscares.com/)
Patient Organizations (POs)	Financial support and engagement with POs to better serve patient needs collectively, which helps UT and our partners in the following areas: • Identify and address unmet needs among a wide variety of patients; • Gather patient insights to integrate into strategic organizational decisions; • Co-create educational materials to improve therapy literacy and adherence; and • Raise awareness about clinical trials (for a short list of POs with which UT engages). For more, see: https://www.unither.com/patients/patient-organizations
Employees	• Town halls • Regular company-wide emails and mailings from senior leadership • Performance management programs • Annual employee surveys • Open door policy for ongoing, informal engagement

STAKEHOLDER GROUP	HOW WE ENGAGE
Health Care Professionals and Health Care Organizations	• Interactions through our corporate website and through the PAH Initiative, Neuroblastoma*info*, and *United Therapeutics* Cares • Participation in a wide range of public forums to communicate safety and efficacy of our treatments • Through advisory boards and other programs to learn the views of HCPs • Through the training we offer to nursing or specialty pharmacy **(SP)** staff on our products and treatments
Investors	• Quarterly earnings conference calls open to investors and available on our website • Participation in sell-side conference presentations • Annual Meeting of Shareholders • Investor Relations website • Meetings with large institutional investors and other shareholders, including direct shareholder engagement by our Lead Independent Director/Chair of the Compensation Committee and Chair of the Nominating and Governance Committee • In 2024, we reached out twice to shareholders that collectively held over 70 percent of our outstanding shares, and we held meetings with eight shareholders that collectively held 27 percent of our outstanding shares; investors were invited to engage on our 2024 Corporate Responsibility and Public Benefit Report and governance topics
Governmental Entities	• In-depth discussions on our sustainable building and environmental, health, safety, and other sustainability practices
Community Groups and the Planet	• Volunteering and financial support • Tours of, and presentations on, the *Unisphere*, *Phase Five*, and our other net-zero energy and LEED-certified properties

Our 2024 PBC Key Metric Summary

Since our founding, we have operated with a patient-driven mission, strong values, and a long-term vision. In 2021, we converted our company from a traditional Delaware corporation into a Delaware PBC. This aligns our legal form with our longstanding commitment to serve our patients and other stakeholders, and, among other benefits, enhances our ability to create superior and sustainable value for our shareholders.

A Delaware PBC is distinct from a traditional corporation in two primary ways:

- A PBC adopts a public benefit purpose in its certificate of incorporation that is intended to have positive effects on a category of persons, entities, or communities affected by our operations other than solely shareholder financial interests.
- In making decisions, directors of a PBC are required to balance the interests of shareholders, the interests of stakeholders materially affected by the PBC's conduct, and pursuit of the corporation's public benefit purpose.

Our public benefit purpose is to provide a brighter future for patients through the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. Our first purpose helps delay or avoid the need for a transplant, while the second purpose enables a patient to have a transplant when they need one.

To achieve our purpose, we seek to make positive impacts on patients, on our people, whom we call *Unitherians*, and on the planet. The chart on the following page illustrates some of how we do so.

An experiment in a UT lab

OUR 2024 PBC KEY METRIC SUMMARY

Our PBC Goals		Key Metrics	2024 Highlights	Report References
Our Patients	**Address Unserved Needs** We aim to conduct the most insightful clinical trials with our medicines in areas of high unmet medical need.	Number of patients being treated with our therapies R&D milestones, including clinical trial results, regulatory approvals, and progress on R&D projects	✔ More than 15,500 patients started or continued treatment on our therapies, including 162 patients benefiting from our centralized EVLP service; celebrated the 500th transplant of a lung processed through our *ex vivo* lung perfusion (**EVLP**) service since its launch ✔ Invested $481 million in R&D in 2024 ✔ Supported 15 ongoing clinical trials with more than 3,000 volunteer participants ✔ Achieved full enrollment of *TETON 2* study of inhaled treprostinil for the treatment of idiopathic pulmonary fibrosis (**IPF**), part of a three-study global *TETON* clinical trial program evaluating the use of inhaled treprostinil in IPF and a similar condition, progressive pulmonary fibrosis (**PPF**) ✔ Secured Investigational New Drug (**IND**) clearance for our phase 1 ***miroliverELAP®*** clinical study in 2024 and submitted IND for the ***UKidney™*** EXPAND study (cleared in 2025) ✔ Launched our first clinical-scale designated pathogen-free (**DPF**) facility to produce xeno-organs ✔ Provided organs for two successful xenotransplants in 2024, both into living humans	Page 13
	No Patient Left Behind We aim to ensure that all patients who are appropriate for use of our medicines can do so, regardless of their financial situation.	Patient Assistance Programs (**PAPs**) Reliable Supply: Inventory and Supply Chain Reliability	✔ Provided patient assistance and support programs, delivering education, insurance navigation support, and more to over 34,000 patients since 2010, including a $0 co-pay card for pulmonary hypertension (**PH**) products for eligible patients ✔ Launched a new integrated patient assistance program for PH products, called *United Therapeutics Cares* ✔ Had Zero Good Manufacturing Practice (**GMP**) related issues at UT-owned facilities that would prevent use or approval of our products ✔ Maintained two-year or more inventory for most of our therapies	Page 13

Our xenotransplantion products are investigational-stage products. United Therapeutics is preparing for clinical trials of our xenokidney, xenothymokidney, and xenoheart products. The two xenotransplants into living humans in 2024 using UT organs were authorized by the U.S. Food and Drug Administration (**FDA**) under the expanded access pathway, sometimes called "compassionate use."

OUR 2024 PBC KEY METRIC SUMMARY

Our PBC Goals		Key Metrics	2024 Highlights	Report References
Our People	**Be a Destination Employer** We aim for United Therapeutics to be a destination employer by creating a mission-centric and inclusive environment where *Unitherians* are inspired by the challenging work ahead of us and the opportunity to grow and advance their careers.	Voluntary turnover Inclusion and belonging programs Employee engagement as measured by surveys Workforce demographics	✔ Voluntary turnover of 4.6%, compared to a 11% industry average* ✔ Expanded benefits important to our employees, now offering medical, dental, and vision benefits to part-time employees; increasing our adoption assistance program for eligible full-and part-time employees, and more ✔ More than 90% of employees who responded to the Great Places to Work survey from 2018 through 2025 consider UT a Great Place to Work ✔ Overall workforce demographics: 52% identify as women, 48% identify as men, 36% identify as racially/ethnically diverse, and 64% identify as white	Page 29
Our Planet	**Operate Sustainably** We aim to mitigate our environmental impact and operate in a sustainable fashion.	New construction site net zero energy when feasible Environmental data trends (e.g., energy, water, waste) Progress toward assurable Scope 1 and 2 greenhouse gas (**GHG**) emissions inventories	✔ Maintained the operational efficiency of our four LEED Certified properties, representing ~20% of our total square footage, and broke ground on our newest sustainable building, a cGMP** mass timber pharmaceutical manufacturing facility ✔ Maintained almost 7-MW onsite solar capacity and 84 free-to-use electric vehicle (**EV**) charging stations across our campuses ✔ Preparing to report Scope 1 and 2 GHG emissions	Page 37

* Industry data from Aon/Radford Turnover study; data published December 2024 | U.S. Life Sciences: Biotech/Pharma | Date range for 2024 industry data is June 2023 – June 2024

** cGMP = current Good Manufacturing Practices. These are manufacturing practices and controls designed to ensure that manufactured products are consistently produced and controlled according to set quality standards.

OUR 2024 PBC KEY METRIC SUMMARY

Our PBC Goals	Key Metrics	2024 Highlights	Report References
	Develop initial climate risk and opportunity assessment by end of 2025	✔ Preparing TCFD report for publication separate from this Report. ✔ Fully converted over to smaller packaging with reduced environmental impact for nebulized Tyvaso compared to previous packaging	
	Integrate environmental principles to the extent possible into new product packaging		

GRI Standards

GRI is an international independent standards organization that helps business, governments, and other organizations understand and communicate their impacts on various issues. We have applied the GRI Sustainability Reporting Standards as an identification and cross-reference tool to make meaningful data accessible to our stakeholders. The "2025 Report" refers to United Therapeutics Corporation's (**UT**) FY 2024 Corporate Responsibility and Public Benefit Report, available here: https://corporateresponsibility.unither.com/

In addition to the 2025 Report, we include cross-references to the following core UT websites and our other public filings, available on our investor relations website and at sec.gov:

Corporate website: https://www.unither.com/home

Corporate responsibility website: https://corporateresponsibility.unither.com/

Investor relations website: https://ir.unither.com/

Statement of use	UT has reported the information cited in this GRI content index for the period January 1, 2024 through December 31, 2024 with reference to the GRI Standards.
GRI 1 used	GRI 1: Foundation 2021

GRI STANDARD	DISCLOSURE	LOCATION
GRI 2: General Disclosures 2021	2-1 Organizational details	United Therapeutics Corporation is a publicly-traded (**Nasdaq: UTHR**), public benefit corporation incorporated in Delaware. Co-headquarters at Silver Spring, Md. and Research Triangle Park, N.C. **2025 Report: Our Business and Purpose** (starting on pg. 4) **2024 Form 10-K: Item 1. Business – Overview** (pg. 3), **Item 2. Properties** (starting on pg. 51) **Corporate Website**: unither.com

GRI STANDARD	DISCLOSURE	LOCATION
	2-2 Entities included in the organization's sustainability reporting	**2024 Form 10-K:** Exhibit 21
GRI 2: General Disclosures 2021	2-3 Reporting period, frequency and contact point	**Reporting period:** January 1, 2024 through December 31, 2024, our fiscal 2024 year. In some cases, we include data and information about programs and activities relevant to our business priorities that occurred in the 2025 fiscal year, as noted. **Reporting cycle:** Annual **Publication date of the report:** September 12, 2025 **Contact point for questions regarding the report:** https://ir.unither.com/contact-ir
	2-4 Restatements of information	None.
	2-5 External assurance	Not applicable.
	2-6 Activities, value chain and other business relationships	UT is the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation. Our public benefit purpose is to provide a brighter future for patients through the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. At the same time, we seek to provide our shareholders with superior financial performance and our communities with earth-sensitive energy utilization. **2025 Report: Our Business and Purpose** (starting on pg. 4) **2024 Form 10-K: Item 1. Business** (starting on pg. 3) **Corporate website > About Us**: https://www.unither.com/home
	2-7 Employees	**2025 Report: Our People > 2024 Highlights** (pg. 29)

GRI STANDARD	DISCLOSURE	LOCATION
	2-8 Workers who are not employees	Contingent workers make up 4% of UT's workforce, and we do not experience seasonal variations of our workforce.
	2-9 Governance structure and composition	**2025 Report: Governance** (starting on pg. 46) **2025 Proxy Statement: Our Corporate Governance** (starting on pg. 13) **Investor Relations website > Corporate Governance:** https://ir.unither.com/corporate-governance
	2-10 Nomination and selection of the highest governance body	**2025 Proxy Statement: Our Corporate Governance > Board Composition and Refreshment** (starting on pg. 13)
	2-11 Chair of the highest governance body	**2025 Proxy Statement: Board Structure and Operations** (pg. 26)
GRI 2: General Disclosures 2021	2-12 Role of the highest governance body in overseeing the management of impacts	**2025 Report: PBC Governance** (starting on pg. 47) **2025 Proxy Statement: Key Areas of Board Oversight** (starting on pg. 29) **Committee Charter Documents:** https://ir.unither.com/corporate-governance

GRI STANDARD	DISCLOSURE	LOCATION
	2-13 Delegation of responsibility for managing impacts	Program or functional area owners are responsible for managing any environmental and social impacts within their domains. For more information, see: **2025 Report: Governance** (starting on pg. 46) **Topic Overview documents**: https://corporateresponsibility.unither.com/ reports-and-resources • Data Security • Enterprise Risk Management and Operational Resilience • Ethics • Global Patient Safety and Vigilance • Good Manufacturing Practices • Grants and Giving • Our Culture and People • Patient Centricity • Sustainable Facilities
	2-14 Role of the highest governance body in sustainability reporting	**2025 Report: Governance** (starting on pg. 46) **Committee Charter Documents:** https://ir.unither.com/corporate-governance
	2-15 Conflicts of interest	**2025 Report: Ethics and Compliance** (pg. 49) **2025 Proxy Statement: Our Corporate Governance > Board Composition and Refreshment** (starting on pg. 13) **Code of Conduct:** https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/ documents/corporate-governance/Code-of-Conduct-and-Business-Ethics.pdf **Ethics Overview:** https://corporateresponsibility.unither.com/~/media/Files/U/Unither-Corp/reports-and-resources/UT-Ethics-Overview.pdf

GRI STANDARD	DISCLOSURE	LOCATION
GRI 2: General Disclosures 2021	2-16 Communication of critical concerns	See response to **indicator 2-15**. In addition to the resources listed there, see the following: • **2025 Proxy Statement: Shareholder Engagement** (pg. 32) • **2025 Report: Our Practices** (starting on pg. 45)
	2-17 Collective knowledge of the highest governance body	**2025 Proxy Statement: Board Skills** (starting on pg. 16), **2025 Director Nominees** (starting on pg. 18), **Board Education** (pg. 31)
	2-18 Evaluation of the performance of the highest governance body	**2025 Proxy Statement: Our Corporate Governance > Board Composition and Refreshment** (starting on pg. 13) **Nominating and Governance Committee Charter:** https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/corporate-governance/nominating-and-governance-committee-charter-4-24-2025.pdf **Corporate Governance Guidelines:** https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/corporate-governance/corporate-governance-guidelines-4-24-2025.pdf
	2-19 Remuneration policies	We pay employees a minimum base salary of $62,500 (with a total target of approximately $75,000 per year including each employee's bonus opportunity), well above all applicable minimum wage levels. **2025 Proxy Statement: Non-Employee Director Compensation** (starting on pg. 33), **Executive Compensation** (starting on pg. 36)
	2-20 Process to determine remuneration	See response to **indicator 2-19**.
	2-21 Annual total compensation ratio	**2025 Proxy: Pay Ratio** (pg. 68)

GRI STANDARD	DISCLOSURE	LOCATION
	2-22 Statement on sustainable development strategy	**2025 Report: A Message from Our CEO** (pg. 2), **Our 2024 PBC, Corporate Responsibility, and Resilience Priorities** (starting on pg. 9)
GRI 2: General Disclosures 2021	2-23 Policy commitments	**2025 Report: Our 2024 PBC Goals, Corporate Responsibility, and Resilience Priorities** (starting on pg. 9), **Product Quality and Patient Safety** (starting on pg. 21) **Quality Operations–Quality Policy Statement** (pg. 23), **Our Pricing Principles** (pg. 27), **Environmental Stewardship - Environmental Health, Safety, and Sustainability (EHSS) Policy Statement** (pg. 38), **Ethics and Compliance** (starting on pg. 49) Also see (available through https://www.unither.com/): • **Animal Welfare Policy:** https://corporateresponsibility.unither.com/~/media/Files/U/ Unither-Corp/reports-and-resources/ut-animal-welfare-policy.pdf • **Our Code of Conduct:** https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/ documents/corporate-governance/Code-of-Conduct-and-Business-Ethics.pdf • **Our Corporate Governance Guidelines:** https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/corporate-governance/corporate-governance-guidelines-4-24-2025.pdf • **Our Privacy Policy:** https://www.unither.com/privacy

GRI STANDARD	DISCLOSURE	LOCATION
	2-24 Embedding policy commitments	See response to **indicator 2-23**. In addition to the resources listed there, see the following: **All Topic Overviews**, in particular the following, available at https://corporateresponsibility.unither.com/reports-and-resources • Data Security • Enterprise Risk Management and Operational Resilience • Ethics • Global Patient Safety and Vigilance • Good Manufacturing Practices • Grants and Giving • Organ Manufacturing • Our Culture and People • Patient Centricity • Sustainable Facilities
GRI 2: General Disclosures 2021	2-25 Processes to remediate negative impacts	**2025 Report: Our 2024 PBC, Corporate Responsibility, and Resilience Priorities** (starting on pg. 9), **Product Quality and Patient Safety** (starting on pg. 21), **Eco-Resilience** (starting on pg. 38), **Our Practices** (starting on pg. 45) Also see: **Topic Overviews**, in particular the following, available at https://corporateresponsibility.unither.com/reports-and-resources • Data Security • Enterprise Risk Management and Operational Resilience • Ethics • Global Patient Safety and Vigilance • Good Manufacturing Practices

GRI STANDARD	DISCLOSURE	LOCATION
	2-26 Mechanisms for seeking advice and raising concerns	We have multiple mechanisms available to UT employees, patients, providers, and others, including those found here: • **2025 Report: Our Practices** (starting on pg. 45), which covers our internal EthicsPoint hotline; • **Overview of Our Safety Program** (starting on pg. 33), which covers the reporting tool available to all *Unitherians* in addition to employee-led safety committees; and • **Product Quality and Patient Safety** (starting on pg. 21), which lists our adverse impact hotline. Also see: **Topic Overviews**, in particular the following, available at https://corporateresponsibility.unither.com/reports-and-resources • Data Security • Enterprise Risk Management and Operational Resilience • Ethics • Global Patient Safety and Vigilance • Good Manufacturing Practices • Patient Centricity

GRI STANDARD	DISCLOSURE	LOCATION
GRI 2: General Disclosures 2021	2-27 Compliance with laws and regulations	**2025 Report: Ethics and Compliance** (starting on pg. 49), **Product Quality and Patient Safety** (starting on pg. 21), **Quality Operations** (pg. 23), **Overview of our Safety Program** (starting on pg. 33), **and Ecosystem Impact Management** (starting on pg. 43). **2024 Form 10-K: Item 1. Business – Governmental Regulation** (starting on pg. 20), **including Environmental Matters and Human Capital** (starting on pg. 32), **Item 1A. Risk Factors** (starting on pg. 35), **Item 8. Financial Statements and Supplementary Data –Note 14. Litigation** (starting on pg. F-34) Also see (available through https://www.unither.com/): • **Our Code of Conduct:** https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/corporate-governance/Code-of-Conduct-and-Business-Ethics.pdf • **Our Privacy Policy:** https://www.unither.com/privacy • **Our UK Tax Strategy:** https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/corporate-governance/utel-tax-strategy-12-31-24.pdf • **Our Conflict Minerals Disclosure:** https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/corporate-governance/2025-conflict-minerals-disclosure-5-29-2025.pdf • **Our California Compliance Program Declaration:** https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/corporate-governance/california-compliance-program-declaration-2024-december-01-v3.pdf
	2-28 Membership associations	We maintain strategic memberships in local, regional, national, and international associations and/or organizations unique to biopharma, environmental, regional, and community-oriented matters.

GRI STANDARD	DISCLOSURE	LOCATION
	2-29 Approach to stakeholder engagement	Shareholder engagement is a core part of our corporate governance process, and includes direct involvement from our Board. Engagement with other relevant stakeholders occurs throughout our organization at the business unit level. **2025 Proxy: Shareholder Engagement** (pg. 31) **2025 Report: Our 2024 PBC Goals, Corporate Responsibility, and Resilience Priorities** (starting on pg. 9), **About This Report and Stakeholder Engagement** (starting on pg. 57)
	2-30 Collective bargaining agreements	None.
GRI 3: Material Topics 2021	3-1 Process to determine material topics	**2025 Report: Our 2024 PBC Goals, Corporate Responsibility, and Resilience Priorities** (starting on pg. 9), **About This Report and Stakeholder Engagement** (starting on pg. 57)
	3-2 List of material topics	**2025 Report: Our 2024 PBC Goals, Corporate Responsibility, and Resilience Priorities** (starting on pg. 9)
	3-3 Management of material topics	**2025 Report: Our Business and Purpose** (starting on pg. 4), **Our 2024 PBC Goals, Corporate Responsibility, and Resilience Priorities** (starting on pg. 9), **Governance** (starting on pg. 46)
GRI 201: Economic Performance 2016	201-1 Direct economic value generated and distributed	**2025 Report: 2024 Year in Review** (pg. 5)
	201-2 Financial implications and other risks and opportunities due to climate change	We intend to issue a TCFD report separate from this Report.

GRI STANDARD	DISCLOSURE	LOCATION
	201-3 Defined benefit plan obligations and other retirement plans	**2024 Form 10-K: Item 8. Financial Statements and Supplementary Data – Note 11. Employee Benefit Plans** (starting on pg. F-30) As of December 31, 2024, we had 99% participation in our U.S. 401(k) plan.
GRI 202: Market Presence 2016	202-1 Ratios of standard entry level wage by gender compared to local minimum wage	We pay all employees a minimum base salary of $62,500 (with a total of approximately $75,000 per year including each employee's bonus opportunity), well above all applicable minimum wage levels. We do not break out this information by demographics. See the following for more information: • **2025 Proxy Pay Ratio** (pg. 68) • **Our Culture and People Overview:** https://corporateresponsibility.unither.com/~/media/Files/U/Unither-Corp/reports-and-resources/UT-Culture-and-People-Overview.pdf • **2025 Report: Our People** (starting on pg. 28)
GRI 203: Indirect Economic Impacts 2016	203-1 Infrastructure investments and services supported	UT's philosophical approach to infrastructure development is to benefit the larger community in addition to UT. See our **Sustainable Facilities Overview** for more information about how our team enabled a building code change that enables the use of geoexchange wells in Montgomery County, Md. (https://corporateresponsibility.unither.com/~/media/Files/U/Unither-Corp/reports-and-resources/UT-Sustainable-Facilities-Overview.pdf). Our organ transplant ecosystem support, detailed in our **Organ Manufacturing Overview** (https://corporateresponsibility.unither.com/~/media/Files/U/Unither-Corp/reports-and-resources/ut-organ-manufacturing-overview.pdf) showcase the services we provided that provide public benefit. Taken alongside our **Grants and Giving Overview** (https://corporateresponsibility.unither.com/~/media/Files/U/Unither-Corp/reports-and-resources/ut-grants-and-giving-overview. pdf), we believe we are making a positive contribution to the communities we serve. The **Topic Overviews** included above, in addition to Impact Stories that also touch on some of the investments and services we support, are available through **https://corporateresponsibility.unither.com/reports-and-resources.**

GRI STANDARD	DISCLOSURE	LOCATION
	203-2 Significant indirect economic impacts	See response to **indicator 203-1**. In addition to their direct impacts, we believe that these activities contribute indirectly and positively to economic outcomes throughout our patient and local communities.
GRI 204: Procurement Practices 2016	204-1 Proportion of spending on local suppliers	We track our spend on our major building projects, emphasizing selection of vendors and service providers located in the county or state where the project is located where feasible to lessen the embodied carbon of the material. For example, among the top six objectives for the company's *Phase Five* buildout (named Project Lightyear during construction), was to use lower embodied carbon products. See our **Sustainable Facilities Overview** (https://corporateresponsibility.unither.com/~/media/ Files/U/Unither-Corp/reports-and-resources/UT-Sustainable-Facilities-Overview.pdf) for more information about our sustainable building approach. In addition, most of the 600 pre-qualified cGMP suppliers are based in the North America.
GRI 205: Anti-corruption 2016	205-1 Operations assessed for risks related to corruption	**2025 Report: Ethics and Compliance** (pg. 49) and our **Ethics Overview** (https://corporateresponsibility.unither.com/~/media/Files/U/Unither-Corp/reports-and-resources/ut-ethics-overview.pdf).
	205-2 Communication and training about anti-corruption policies and procedures	See response to **indicator 205-1**. We had 100% completion of assigned annual Code of Conduct training. See **2025 Report: Talent Acquisition, Management, and Development** (starting on pg. 31).
	205-3 Confirmed incidents of corruption and actions taken	None.
GRI 206: Anti-competitive Behavior 2016	206-1 Legal actions for anti-competitive behavior, anti-trust, and monopoly practices	**2024 Form 10-K: Item 8. Financial Statements and Supplementary Data – Note 14. Litigation** (starting on pg. F-34)

GRI STANDARD	DISCLOSURE	LOCATION
GRI 207: Tax 2019	207-1 Approach to tax	We actively monitor our adherence to applicable tax laws, regulations, and disclosure requirements across the jurisdictions in which we do business. See our **UK Tax Strategy:** https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/corporate-governance/utel-tax-strategy-12-31-24.pdf
	207-2 Tax governance, control, and risk management	Our Vice President of Tax and Chief Financial Officer are responsible for overseeing our global tax affairs and tax risk management. Where appropriate, tax risks are discussed with and reviewed by the Audit Committee of the Board of Directors, as well as communicated to our external auditors.
GRI 301: Materials 2016	301-3 Reclaimed products and their packaging materials	We participate in the Pharmaceutical Product Stewardship Work Group (**PPSWG**) MyOldMeds industry takeback program. https://myoldmeds.com/
GRI 302: Energy 2016	302-1 Energy consumption within the organization	One of our PBC goals and objectives is to ***Operate Sustainably***, which has been a long-held guiding principle in our building practices and operations. Several of our PBC key metrics relate directly to monitoring and mitigating our environmental impact. We have approximately 7-MW of onsite solar capacity and track energy data but do not currently report on it. See **2025 Report: Eco-Resilience** (starting on pg. 38).
	302-2 Energy consumption outside of the organization	See response to **indicator 302-1**. We have also begun evaluating our Scope 3 category energy sources and emissions.
	302-3 Energy intensity	See response to **indicator 302-1**.
	302-4 Reduction of energy consumption	See response to **indicator 302-1**.

GRI STANDARD	DISCLOSURE	LOCATION
	302-5 Reductions in energy requirements of products and services	See response to **indicator 302-1**.
GRI 303: Water and Effluents 2018	303-1 Interactions with water as a shared resource	**2025 Report: Water Stewardship** (pg. 43)
	303-2 Management of water discharge-related impacts	See response to **indicator 303-1**. Sites that have wastewater discharge permits have processes in place to support compliance with water quality standards for the quality of effluent discharge established by the conditions contained in the permits, and we have received recognition for our water management practices.
	303-3 Water withdrawal	One of our PBC goals and objectives is to ***Operate Sustainably,*** which has been a long-held guiding principle in our building practices and operations. We track water data but do not currently report on it. See **2025 Report: Ecosystem Impact Management** (starting on pg. 43)
	303-4 Water discharge	See response to **indicator 303-3**.
	303-5 Water consumption	See response to **indicator 303-3**.
GRI 305: Emissions 2016	305-1 Direct (Scope 1) GHG emissions	One of our PBC goals and objectives is to ***Operate Sustainably***, which has been a long-held guiding principle in our building practices and operations. Several of our PBC key metrics relate directly to monitoring and mitigating our environmental impact. We intend to disclose this data in accordance with regulatory requirements in the State of California or elsewhere. See **2025 Report: Our Approach to Climate** (pg. 43)
	305-2 Energy indirect (Scope 2) GHG emissions	See response to **indicator 305-1**.

GRI STANDARD	DISCLOSURE	LOCATION
	305-3 Other indirect (Scope 3) GHG emissions	See response to **indicator 305-1**.
	305-4 GHG emissions intensity	See response to **indicator 305-1**.
	305-5 Reduction of GHG emissions	See response to **indicator 305-1**.
GRI 306: Waste 2020	306-1 Waste generation and significant waste-related impacts	One of our PBC goals and objectives is to ***Operate Sustainably***, which has been a long-held guiding principle in our building practices and operations. See **2025 Report: Responsible Waste Management** (starting on pg. 43), **Other Sustainability Initiatives** (starting on pg. 44)
	306-2 Management of significant waste-related impacts	See response to **indicator 306-1**.
	306-3 Waste generated	See response to **indicator 306-1**.
	306-4 Waste diverted from disposal	See response to **indicator 306-1**.
	306-5 Waste directed to disposal	See response to **indicator 306-1**.
GRI 401: Employment 2016	401-1 New employee hires and employee turnover	We had 223 new hires in 2024. Our employee turnover rate is consistently lower than industry average, with 4.6% voluntary turnover in 2024 compared to 11% industry average. Our recruitment and retention practices are robust, so our involuntary turnover rates are also low at 2%. **2025 Report: Our People** (starting on pg. 28)

GRI STANDARD	DISCLOSURE	LOCATION
	401-2 Benefits provided to full-time employees that are not provided to temporary or part-time employees	Many benefits UT provides are available to both full- and part-time employees. For example, we provide medical, dental, and vision benefits to full- and part-time employees, and beginning in 2024, part-time employees accrue prorated paid time off monthly based on their core work schedule and tenure. Part-time employees are also eligible to participate in our 401-k and our employee assistance program. Part-time employees are not eligible to participate in our employee stock purchase plan (**ESPP**) and are not eligible for tuition assistance. See **Our Culture and People Overview** for more: https://corporateresponsibility.unither.com/~/media/Files/U/Unither-Corp/reports-and-resources/UT-Culture-and-People-Overview.pdf
	401-3 Parental leave	Full-time employees are eligible for paid parental bonding leave. See **Our Culture and People Overview** for more: https://corporateresponsibility.unither.com/~/media/Files/U/Unither-Corp/reports-and-resources/UT-Culture-and-People-Overview.pdf
GRI 403: Occupational Health and Safety 2018	403-1 Occupational health and safety management system	**2025 Report: Safe and Healthy Workplaces** (starting on pg. 33)
	403-2 Hazard identification, risk assessment, and incident investigation	See response to **indicator 403-1**, in particular the **Overview of our Safety Program** introduction (pg. 33).
	403-3 Occupational health services	See response to **indicator 403-1**.
	403-4 Worker participation, consultation, and communication on occupational health and safety	See response to **indicator 403-1**, in particular **Train to Empower** (pg. 34).

GRI STANDARD	DISCLOSURE	LOCATION
	403-5 Worker training on occupational health and safety	See response to **indicator 403-1**. We had 100% completion of required annual incident management training. See **2025 Report: Talent Acquisition, Management, and Development** (starting on pg. 31).
	403-6 Promotion of worker health	See response to **indicator 403-1.**
	403-7 Prevention and mitigation of occupational health and safety impacts directly linked by business relationships	See response to **indicator 403-1**.
	403-8 Workers covered by an occupational health and safety management system	Our full-time and part-time employees, including contractors working at UT locations are covered by UT's occupational health and safety management system. See **2025 Report: Eco-Resilience - Environmental Health, Safety, and Sustainability (EHSS) Policy Statement** (pg. 38) for more information.
	403-9 Work-related injuries	**2025 Proxy Statement** (pg. 8). We had zero fatalities and 10 Occupational Safety and Health Administration (**OSHA**) recordable incidents for our U.S. operations in 2024, with an overall incidence rate of 0.91 per 100 full-time workers. This is below the average incidence rate of 1.7 recordable cases per 100 full-time workers for the pharmaceutical preparation manufacturing industry (based on the most current U.S. Bureau of Labor Statistics Injuries, Illnesses, and Fatalities industry average data).
	403-10 Work-related ill health	See response to **indicator 403-9**.

GRI STANDARD	DISCLOSURE	LOCATION
	404-3 Percentage of employees receiving regular performance and career development reviews	All managers and employees are encouraged to participate in regular performance and career development opportunities. In 2024, 87% of employees completed annual performance conversations, and 90% completed annual development plans and goals.
GRI 405: Diversity and Equal Opportunity 2016	405-1 Diversity of governance bodies and employees	**2025 Report: Our People** (starting on pg. 28) and our **Our 2024 PBC Key Metric Summary** (starting on pg. 60) Overall UT workforce demographics: 52% identify as women, 48% identify as men, 36% identify as racially/ethnically diverse, and 64% identify as white. Board demographics: 42% identify as women, 68% identify as men, 25% identify as racially/ethnically diverse, and 75% identify as white.
GRI 406: Non-discrimination 2016	406-1 Incidents of discrimination and corrective actions taken	Material incidents would be reported as appropriate in applicable U.S. Securities and Exchange Committee (**SEC**) filings.
GRI 416: Customer Health and Safety 2016	416-1 Assessment of the health and safety impacts of product and service categories	**2025 Report: Product Quality and Patient Safety** (starting on pg. 21)
	416-2 Incidents of non-compliance concerning the health and safety impacts of products and services	Visit the **FDA MedWatch** website for more information. (https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program) Visit the **FDA FAERS** website for more information. (https://www.fda.gov/drugs/drug-approvals-and-databases/fda-adverse-event-reporting-system-faers)

GRI STANDARD	DISCLOSURE	LOCATION
GRI 417: Marketing and Labeling 2016	417-1 Requirements for product and service information and labeling	**2024 Form 10-K: Item 1. Business – Governmental Regulation** (starting on pg. 20)
	417-2 Incidents of non-compliance concerning product and service information and labeling	None.
	417-3 Incidents of non-compliance concerning marketing communications	Material incidents would be reported as appropriate in applicable U.S. Securities and Exchange Committee (**SEC**) filings.
GRI 418: Customer Privacy 2016	418-1 Substantiated complaints concerning breaches of customer privacy and losses of customer data	None.

SASB Topics

SASB is an independent, private sector standards-setting organization whose mission is to help businesses around the world identify, manage, and report on the sustainability topics that SASB believes matter most to investors. We have considered the industry standards (as defined by SASB's Industry Classification System) for the Biotechnology and Pharmaceuticals Sector, and the table below represents some topics that we believe are relevant to our company and that are discussed in our 2025 Corporate Responsibility and Public Benefit Report (our "2025 Report", which covers 2024 performance). In certain instances, and as noted below, a specific SASB topic may be discussed generally in our 2025 Report but we do not currently track or report progress on the corresponding SASB metrics.

SASB TOPIC	CODE	ACCOUNTING METRIC	2024 EXPLANATION OR LOCATION (REPORTED IN 2025 REPORT)
Safety of Clinical Trial Participants	HC-BP-210a.1	Discussion of, by world region, management process for ensuring quality and patient safety during clinical trials	Detailed discussion of our Global Patient Safety program, which includes quality and patient safety during clinical trials, is available in the following resources: ✓ **Our Patient Safety and Vigilance Overview:** https://corporateresponsibility.unither.com/~/media/Files/U/Unither-Corp/reports-and-resources/UT-Patient-Safety-Vigilance-Program-Overview.pdf ✓ **2025 Report:** Product Quality and Patient Safety (starting on pg. 21)
	HC-BP-210a.2	Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)	None.
	HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	We do not have any clinical trials in less developed countries. Material losses and legal proceedings are reported as appropriate in applicable U.S. SEC filings.

SASB TOPIC	CODE	ACCOUNTING METRIC	2023 EXPLANATION OR LOCATION (REPORTED IN 2024 REPORT)
Access to Medicine	HC-BP-240a.1	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	Not applicable. We are a growth public benefit company focused on rare diseases in the North American market. Therefore, we are not included in the Access to Medicine Index because the diseases we cover are not among those in scope of the index.
	HC-BP-240.2	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	Not applicable. None of our products are on the WHO List of Prequalified Medicinal Products because our core therapeutic areas are not in the therapeutic scope of this list.
Affordability and Pricing	HC-BP-240b.2	Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year	As noted in our **2024 Form 10-K** (pg. 12), to the extent we increase the price of our core therapeutics — Tyvaso DPI, nebulized Tyvaso, Remodulin, the Remunity Pump, and Orenitram — increases are typically in the single-digit percentages per year. We sell Adcirca at prices established by **Eli Lilly**. **(2024 Form 10-K,** pg. 7) See additional pricing discussion in the **2025 Report under Market Access and Pricing** (starting on pg. 27).
	HC-BP-240b.3	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year	See response to **HC-BP-240b.2**.

SASB TOPIC	CODE	ACCOUNTING METRIC	2024 EXPLANATION OR LOCATION (REPORTED IN 2025 REPORT)
Drug Safety	HC-BP-250a.1	List of products listed in the Food and Drug Administration's (FDA) MedWatch Safety Alerts for Human Medical Products database	Visit the **FDA MedWatch** website for more information. (https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program) For information about our patient safety and product quality and GMP programs, see: ✓ **Our Patient Safety and Vigilance Overview:** https://corporateresponsibility.unither.com/~/media/Files/U/Unither-Corp/reports-and-resources/UT-Patient-Safety-Vigilance-Program-Overview.pdf ✓ **Our Good Manufacturing Practices Overview:** https://corporateresponsibility.unither.com/~/media/Files/U/Unither-Corp/reports-and-resources/UT-Good-Manufacturing-Practices-Overview.pdf
	HC-BP-250a.2	Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System	Visit the **FDA FAERS** website for more information. (https://www.fda.gov/drugs/drug-approvals-and-databases/fda-adverse-event-reporting-system-faers)
	HC-BP-250a.3	Number of recalls issued, total units recalled	None.
	HC-BP-250a.5	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	None.
Counterfeit Drugs	HC-BP-260a.1	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	**Our Patient Safety and Vigilance Overview - Anti-Counterfeiting and Package Serialization:** https://corporateresponsibility.unither.com/~/media/Files/U/Unither-Corp/reports-and-resources/UT-Patient-Safety-Vigilance-Program-Overview.pdf

SASB TOPIC	CODE	ACCOUNTING METRIC	2024 EXPLANATION OR LOCATION (REPORTED IN 2025 REPORT)
	HC-BP-260a.3	Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products	None.
Ethical Marketing	HC-BP-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	None.
	HC-BP-270a.2	Description of code of ethics governing promotion of off-label use of products	We prohibit off-label promotion by UT staff and sales staff are expressly prohibited from responding to questions about off-label information. **Code of Conduct:** https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/corporate-governance/Code-of-Conduct-and-Business-Ethics.pdf
Employee Recruitment, Development and Retention	HC-BP-330a.1	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	UT believes that capacity development in the fields of science in which we work will help create the next generation of talent at UT. UT partners with schools of pharmacy, like the UNC Eschelman School of Pharmacy, to offer specialized fellowships for PharmD graduates. UT established endowed scholarships at three North Carolina-based community colleges to support candidates enrolled in biotechnology programs. And, UT's internship program is designed to nurture future talent, which contributes toward relatively high numbers of interns returning as employees. Detailed discussion of our People programs, which includes talent recruitment and retention efforts, is available in the following resources: ✓ **Our Culture and People Overview:** https://corporateresponsibility.unither.com/~/media/Files/U/Unither-Corp/reports-and-resources/UT-Culture-and-People-Overview.pdf ✓ **2025 Report: Talent Acquisition, Management, and Development** (starting on pg. 31)

SASB TOPIC	CODE	ACCOUNTING METRIC	2024 EXPLANATION OR LOCATION (REPORTED IN 2025 REPORT)
	HC-BP-330a.2	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others	Our employee turnover rate is consistently lower than industry average, with 4.6% voluntary turnover in 2024 compared to 11% industry average. Our involuntary turnover rates are also low at 2%. **2025 Report: Our People > 2024 Progress** (pg. 28)
Business Ethics	HC-BP-510a.1	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	Material losses and legal proceedings are reported as appropriate in applicable U.S. SEC filings.
	HC-BP-510a.2	Description of code of ethics governing interactions with health care professionals	**2025 Report: Our Practices > Ethics and Compliance** (pg. 49) **Code of Conduct:** https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/corporate-governance/Code-of-Conduct-and-Business-Ethics.pdf Also see **UT Ethics Overview:** https://corporateresponsibility.unither.com/~/media/Files/U/Unither-Corp/reports-and-resources/UT-Ethics-Overview.pdf
Activity Metrics	HC-BP-000.A	Number of patients treated	**2025 Report: Our Business and Purpose > 2024 Year in Review** (starting on pg. 5)
	HC-BP-000.B	Number of drugs (1) in portfolio and (2) in R&D (phases 1–3)	**2025 Report: Our Business and Purpose > Our Focus** (starting on pg. 7) Also see our pipeline at https://pipeline.unither.com/



United Therapeutics
A PUBLIC BENEFIT CORPORATION